DE69334351D1 - Biosynthetisches Bindeprotein für Tumormarker - Google Patents

Biosynthetisches Bindeprotein für Tumormarker

Info

Publication number
DE69334351D1
DE69334351D1 DE69334351T DE69334351T DE69334351D1 DE 69334351 D1 DE69334351 D1 DE 69334351D1 DE 69334351 T DE69334351 T DE 69334351T DE 69334351 T DE69334351 T DE 69334351T DE 69334351 D1 DE69334351 D1 DE 69334351D1
Authority
DE
Germany
Prior art keywords
erbb
polypeptide
binding protein
tumor markers
terminus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69334351T
Other languages
German (de)
English (en)
Inventor
David B Ring
L L Houston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of DE69334351D1 publication Critical patent/DE69334351D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69334351T 1992-02-06 1993-02-05 Biosynthetisches Bindeprotein für Tumormarker Expired - Lifetime DE69334351D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83196792A 1992-02-06 1992-02-06

Publications (1)

Publication Number Publication Date
DE69334351D1 true DE69334351D1 (de) 2011-05-12

Family

ID=25260318

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69334351T Expired - Lifetime DE69334351D1 (de) 1992-02-06 1993-02-05 Biosynthetisches Bindeprotein für Tumormarker
DE69333807T Expired - Lifetime DE69333807T2 (de) 1992-02-06 1993-02-05 Marker für krebs und biosynthetisches bindeprotein dafür
DE69334255T Expired - Lifetime DE69334255D1 (de) 1992-02-06 1993-02-05 Marker für Krebs und biosynthetisches Bindeprotein dafür

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69333807T Expired - Lifetime DE69333807T2 (de) 1992-02-06 1993-02-05 Marker für krebs und biosynthetisches bindeprotein dafür
DE69334255T Expired - Lifetime DE69334255D1 (de) 1992-02-06 1993-02-05 Marker für Krebs und biosynthetisches Bindeprotein dafür

Country Status (8)

Country Link
US (6) US5534254A (enExample)
EP (3) EP1997894B1 (enExample)
JP (8) JPH08500962A (enExample)
AT (3) ATE419355T1 (enExample)
AU (1) AU675929B2 (enExample)
CA (2) CA2129663C (enExample)
DE (3) DE69334351D1 (enExample)
WO (1) WO1993016185A2 (enExample)

Families Citing this family (1470)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US6121424A (en) * 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US20050058638A1 (en) * 1987-05-21 2005-03-17 Huston James S. Biosynthetic binding proteins for immuno-targeting
DE68913658T3 (de) * 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
EP0573551B1 (en) * 1991-02-27 2003-05-21 Micromet AG Serine-rich peptide linkers
KR100334697B1 (ko) * 1991-08-05 2002-04-27 리차아드제이마세이 표적화된 촉매 단백질에 의해 활성화되는 선구 약제
US20070031931A1 (en) * 1992-02-06 2007-02-08 Chiron Corporation Biosynthetic binding proteins for immuno-targeting
EP1997894B1 (en) * 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US7754211B2 (en) * 1992-04-10 2010-07-13 Research Development Foundation Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens
US20080152586A1 (en) * 1992-09-25 2008-06-26 Avipep Pty Limited High avidity polyvalent and polyspecific reagents
AU5670194A (en) * 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
DK0672142T3 (da) * 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
ES2126145T3 (es) 1993-09-22 1999-03-16 Medical Res Council Redireccionamiento de anticuerpos.
US5753225A (en) * 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
IT1264083B1 (it) * 1993-12-10 1996-09-10 Enea Ente Nuove Tec Procedimento per la produzione in piante di anticorpi ingegnerizzati, anticorpi prodotti e loro uso in diagnosi e terapia.
US5763733A (en) * 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
AUPO591797A0 (en) * 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
NZ331360A (en) * 1996-03-27 2000-03-27 Genentech Inc an antibody which binds to a ErbB3 protein and reduces heregulin-induced formation of a ErbB2-ErbB3 protein complex
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
DE69739856D1 (de) * 1996-07-03 2010-06-02 Genentech Inc Agonisten für den rezeptor des hepatozyten-wachstumsfaktors und deren anwendungen
WO1998003670A1 (en) * 1996-07-23 1998-01-29 Tanox Pharma B.V. Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways
WO1998005684A2 (en) * 1996-08-05 1998-02-12 President And Fellows Of Havard College Mhc binding peptide oligomers and methods of use
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
DE69841217D1 (de) * 1997-01-13 2009-11-19 Univ Emory Glutathion zur behandlung von influenzainfektionen
WO1998033809A1 (en) * 1997-01-31 1998-08-06 The General Hospital Corporation Compositions and methods for imaging gene expression
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) * 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) * 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20040009166A1 (en) * 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
EP0979102A4 (en) 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
ES2287976T3 (es) 1997-06-13 2007-12-16 Genentech, Inc. Recuperacion de proteinas mediante cromatografia seguida de filtracion sobre una capa cargada.
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
FR2766826B1 (fr) * 1997-08-04 2001-05-18 Pasteur Institut Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
US6737249B1 (en) * 1997-08-22 2004-05-18 Genentech, Inc. Agonist antibodies
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP1947119A3 (en) 1997-12-12 2012-12-19 Genentech, Inc. Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
EP1941905A1 (en) 1998-03-27 2008-07-09 Genentech, Inc. APO-2 Ligand-anti-her-2 antibody synergism
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
WO1999061057A2 (en) * 1998-05-23 1999-12-02 Tanox, Inc. Molecules targeting cd40 and tumor cells
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US7387772B1 (en) * 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7833528B2 (en) * 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
ATE460946T1 (de) * 1998-06-22 2010-04-15 Immunomedics Inc Gebrauch von bispezifischen antikörpern in diagnose und therapie
DE19831429A1 (de) * 1998-07-07 2000-04-27 Jerini Biotools Gmbh Verfahren zur Identifizierung und chemisch-synthetischen Nachahmung von Bindungsstellen auf Proteinen
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
AU1727500A (en) * 1998-11-17 2000-06-05 Tanox, Inc. Bispecific molecules cross-linking itim and itam for therapy
US7118743B2 (en) 1998-11-17 2006-10-10 Tanox, Inc. Bispecific molecules cross-linking ITIM and ITAM for therapy
SI1135498T1 (sl) 1998-11-18 2008-06-30 Genentech Inc Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AR024464A1 (es) 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
BRPI0012196B8 (pt) 1999-06-25 2021-05-25 Genentech Inc artigo industrializado
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
IL147017A0 (en) * 1999-06-25 2002-08-14 Genentech Inc TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
KR101261749B1 (ko) 1999-08-27 2013-05-07 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6794494B1 (en) * 2003-04-14 2004-09-21 Arius Research, Inc. Cancerous disease modifying antibodies
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7172759B2 (en) 2000-02-01 2007-02-06 Pangenetics Bv Induction of cytotoxic T lymphocyte responses using anti-CD40 antibodies
AU4243201A (en) * 2000-02-24 2001-09-03 Eidgenoess Tech Hochschule Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis
US6319694B1 (en) * 2000-03-03 2001-11-20 Genopsys, Inc. Random truncation and amplification of nucleic acid
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
AU2001274809A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
AU5720601A (en) * 2000-04-26 2001-11-07 Elusys Therapeutics Inc Bispecific molecules and uses thereof
AU2001259271A1 (en) * 2000-04-28 2001-11-12 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
CA2407556C (en) 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
AU2001266604A1 (en) * 2000-05-26 2001-12-11 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
JP2004512262A (ja) 2000-06-20 2004-04-22 アイデック　ファーマスーティカルズ　コーポレイション 非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
GB0027328D0 (en) * 2000-06-23 2000-12-27 Aventis Pharma Inc Bioengineered vehicles for targeted nucleic acid delivery
EE200300092A (et) * 2000-09-07 2005-06-15 Schering Aktiengesellschaft EDb-fibronektiinidomeeni retseptor
US20020086814A1 (en) * 2000-11-15 2002-07-04 Brian Storrie B/B-like fragment targeting for the purposes of photodynamic therapy and medical imaging
AU2002231368C1 (en) 2001-01-05 2018-08-16 Amgen Fremont Inc. Antibodies to insulin-like growth factor I receptor
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
ES2366775T3 (es) 2001-04-24 2011-10-25 Merck Patent Gmbh POLITERAPIA UTILIZANDO AGENTES ANTIANGIOGÉNICOS Y TNF(alfa).
CN1195779C (zh) * 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
WO2005010044A2 (en) 2003-07-08 2005-02-03 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
WO2003000113A2 (en) 2001-06-20 2003-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6995171B2 (en) 2001-06-21 2006-02-07 Agouron Pharmaceuticals, Inc. Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
ATE486092T1 (de) 2001-09-18 2010-11-15 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
KR100801388B1 (ko) 2002-01-02 2008-02-05 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
IL162201A0 (en) * 2002-01-03 2005-11-20 Schering Ag New methods for diagnosis and treatment of tumours
DK1472275T3 (da) 2002-02-05 2009-04-14 Genentech Inc Proteinoprensning
US6869787B2 (en) * 2002-02-27 2005-03-22 The United States Of America As Represented By The Secretary Of The Army Ricin vaccine and methods of making and using thereof
ES2429112T3 (es) 2002-04-10 2013-11-13 Genentech, Inc. Variantes de anticuerpos anti-HER2
CA2481509A1 (en) * 2002-04-11 2003-10-23 Suzanna Tatarewicz Her-2 receptor tyrosine kinase molecules and uses thereof
EP2011886A3 (en) 2002-04-16 2009-02-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2005117986A2 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody drug conjugates and methods
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
CA2490659C (en) * 2002-06-28 2014-08-19 Syed V. S. Kashmiri Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
CN101711866A (zh) 2002-07-15 2010-05-26 健泰科生物技术公司 鉴定对用抗ErbB2抗体处理响应的肿瘤的方法
CA2496060C (en) 2002-09-11 2015-08-04 Genentech, Inc. Protein purification by ion exchange chromatography
AU2002951853A0 (en) * 2002-10-04 2002-10-24 Commonwealth Scientific And Industrial Research Organisation Crystal structure of erbb2 and uses thereof
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
EP1572972A4 (en) * 2002-11-21 2007-11-21 Genentech Inc THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES
US20040186160A1 (en) * 2002-12-13 2004-09-23 Sugen, Inc. Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
DK1585743T3 (da) * 2002-12-19 2007-09-17 Pfizer 2-(H-indazol-6-ylamino)-benzamid forbindelser som protein kinase inhibitorer, nyttige til behandling opthalmiske sygdomme
PT2000481E (pt) 2003-02-01 2016-06-17 Tanox Inc Anticorpos anti-ige humana de alta afinidade
OA13151A (en) 2003-02-26 2006-12-13 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors.
CA2520932A1 (en) * 2003-04-03 2004-10-14 Pfizer Inc. Dosage forms comprising ag013736
KR101195295B1 (ko) 2003-04-04 2012-10-29 노파르티스 아게 고농도 항체 및 단백질 제형
ZA200507805B (en) 2003-04-09 2006-12-27 Genentech Inc Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
KR20180132969A (ko) 2003-05-30 2018-12-12 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
JP2007536896A (ja) 2003-06-05 2007-12-20 ジェネンテック・インコーポレーテッド Ｂｌｙｓアンタゴニストとその用途
EP1644039B1 (en) * 2003-06-19 2014-10-01 Genentech, Inc. Compositions and methods for treating coagulation related disorders
SI1648940T1 (sl) 2003-07-28 2016-08-31 Genentech, Inc. Zmanjševanje izluževanja proteina A med afinitetno kromatografijo proteina A
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
MXPA06002256A (es) * 2003-08-29 2006-05-17 Pfizer Naftaleno carboxamidas y sus derivados utiles como agentes anti-angiogenicos.
DE602004017479D1 (de) * 2003-08-29 2008-12-11 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
WO2005021594A2 (en) * 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CN1938046B (zh) 2003-11-06 2014-03-19 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
PT2161283E (pt) 2003-11-17 2014-08-29 Genentech Inc Composições que compreendem anticorpos contra cd79b conjugados a um agente de inibição do crescimento ou agente citotóxico e métodos para o tratamento de tumor de origem hematopoiética
ATE473967T1 (de) * 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
EP2168986A3 (en) 2004-02-19 2010-07-28 Genentech, Inc. CDR-repaired antibodies
BRPI0509580A (pt) * 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
AU2005230848B9 (en) 2004-03-31 2011-06-02 Genentech, Inc. Humanized anti-TGF-beta antibodies
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US20060051345A1 (en) 2004-06-04 2006-03-09 Genentech, Inc. Method for treating multiple sclerosis
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
RU2342159C2 (ru) * 2004-07-16 2008-12-27 Пфайзер Продактс Инк. Комбинированная терапия негематологических злокачественных опухолей с использованием анти-igf-1r-антитела
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
NZ552956A (en) 2004-07-20 2010-03-26 Genentech Inc Inhibitors of angiopoietin-like 4 protein (ANGPTL4), combinations, and their use for treating cancer
RS51601B (sr) * 2004-08-26 2011-08-31 Pfizer Inc. Pirazoli supstituisani sa aminoheteroaril jedinjenja, kao inhibitori protein kinaze
HRP20100298T1 (hr) * 2004-08-26 2010-06-30 Pfizer Inc. Enantiomerno čisti aminoheteroarilni spojevi kao inhibitori proteinskih kinaza
CA2578075A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
ES2325866T3 (es) * 2004-09-21 2009-09-22 Government Of The Usa As Represented By The Secretary Of The Department Of Health And Human Services Procedimiento de deteccion de cancer en base a una reaccion inmune a boris.
BRPI0516284A (pt) 2004-09-23 2008-09-02 Genentech Inc anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
US7964195B2 (en) 2005-01-07 2011-06-21 Diadexus, Inc. Ovr110 antibody compositions and methods of use
JP2008528486A (ja) 2005-01-21 2008-07-31 ジェネンテック・インコーポレーテッド Ｈｅｒ抗体の一定投薬
CA2595395A1 (en) * 2005-02-09 2006-08-17 Genentech, Inc. Inhibiting her2 shedding with matrix metalloprotease antagonists
AU2006214121B9 (en) 2005-02-15 2013-02-14 Duke University Anti-CD19 antibodies and uses in oncology
UA95902C2 (ru) 2005-02-23 2011-09-26 Дженентек, Инк. Способ увеличения времени развития заболевания или выживаемости у раковых пациентов
TW200642695A (en) * 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
AU2006230563B8 (en) 2005-03-31 2010-06-17 Agensys, Inc. Antibodies and related molecules that bind to 161P2F10B proteins
GEP20115226B (en) 2005-04-26 2011-06-10 Pfizer P-cadherin antibodies
AU2006244445B2 (en) 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US7858843B2 (en) 2005-06-06 2010-12-28 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP1917020B1 (en) 2005-07-07 2016-05-25 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
WO2007021423A2 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
WO2007040912A2 (en) * 2005-09-07 2007-04-12 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
EP2372363A1 (en) 2005-09-20 2011-10-05 OSI Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1
MX337061B (es) 2005-11-04 2016-02-11 Genentech Inc Uso de inhibidores de la via del complemento para tratar enfermedades oculares.
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
ZA200804162B (en) 2005-11-21 2009-12-30 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
RU2426742C2 (ru) 2005-12-02 2011-08-20 Дженентек, Инк. Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами
WO2007120334A2 (en) 2005-12-15 2007-10-25 Genentech, Inc. Methods and compositions for targeting polyubiquitin
US7625759B2 (en) 2005-12-19 2009-12-01 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
EP2402373B1 (en) 2006-01-05 2016-10-19 Genentech, Inc. Anti-EphB4 Antibodies and Methods Using Same
BRPI0706530A2 (pt) * 2006-01-13 2011-03-29 Irm Llc métodos e composições para tratamento de doenças alérgicas
BRPI0706540A2 (pt) 2006-01-18 2011-03-29 Merck Patent Gmbh terapia especìfica usando ligantes de integrina para tratar cáncer
EP1988768A2 (en) 2006-02-17 2008-11-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
WO2007103469A2 (en) 2006-03-06 2007-09-13 Aeres Biomedical Ltd. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
US8940871B2 (en) 2006-03-20 2015-01-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
EP2389948A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
CA2649387A1 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
KR20090007792A (ko) 2006-05-09 2009-01-20 화이자 프로덕츠 인크. 시클로알킬아미노산 유도체 및 이들의 제약 조성물
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
AU2007266521C1 (en) 2006-05-30 2012-12-20 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
KR101196184B1 (ko) 2006-06-02 2012-11-01 아베오 파마슈티컬즈, 인크. 간세포 성장 인자 (ｈｇｆ) 결합 단백질
BRPI0712222B1 (pt) 2006-06-02 2021-10-13 Aveo Pharmaceuticals, Inc. Proteína de ligação isolada que se liga ao fator de crescimento de hepatócito humano (hgf), seu uso e método de produção, ácido nucléico, vetor de expressão, célula hospedeira, e métodos para produzir um polipeptídeo que compreende uma região variável da cadeia pesada de imunoglobulina e para produzir um polipeptídeo que compreende uma região variável da cadeia leve de imunoglobulina
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
DK2426150T3 (en) 2006-06-30 2018-01-22 Novo Nordisk As ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
AU2007275654A1 (en) 2006-07-19 2008-01-24 The Trustees Of The University Of Pennsylvania WSX-1/p28 as a target for anti-inflammatory responses
EP2079483A4 (en) 2006-07-29 2010-10-20 Robert Lamar Bjork Jr BISPECIFIC MONOCLONAL ANTIBODIES (SPECIFIC FOR CD3 AND CD11B) THERAPEUTIC MEDICAMENTS
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
JP2010501172A (ja) 2006-08-25 2010-01-21 オンコセラピー・サイエンス株式会社 肺癌に対する予後マーカーおよび治療標的
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008031051A2 (en) 2006-09-08 2008-03-13 United Therapeutics Corporation Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
US20080076139A1 (en) 2006-09-21 2008-03-27 Sharat Singh Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
US8436147B2 (en) 2006-10-27 2013-05-07 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
RU2447449C2 (ru) 2006-11-14 2012-04-10 Дженентек, Инк. Модуляторы нейрональной регенерации
US8470332B2 (en) 2006-11-22 2013-06-25 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
CA2670696A1 (en) 2006-11-27 2008-06-05 Diadexus, Inc. Ovr110 antibody compositions and methods of use
AU2007333805B2 (en) 2006-12-18 2013-07-25 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
MX2009006696A (es) * 2006-12-22 2009-06-30 Novelix Therapeutics Gmbh Tratamiento de diabetes con al menos un anticuerpo especifico del receptor del factor de crecimiento epidermico o uin derivado de este.
PL2101805T3 (pl) 2007-01-18 2013-04-30 Merck Patent Gmbh Ligandy integryn do stosowania w leczeniu nowotworów
PE20081760A1 (es) 2007-02-09 2009-01-01 Genentech Inc Anticuerpos anti-robo4 y sus usos
ES2556380T3 (es) 2007-02-22 2016-01-15 Genentech, Inc. Procedimientos para detectar una enfermedad inflamatoria del intestino
CN103432580A (zh) 2007-03-02 2013-12-11 健泰科生物技术公司 基于低her3表达预测对her二聚化抑制剂的响应
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2008127710A2 (en) 2007-04-13 2008-10-23 Dana Farber Cancer Institute Methods for treating cancer resistant to erbb therapeutics
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
US20090163698A1 (en) * 2007-05-11 2009-06-25 John Joseph Grigsby Method for Preparing Antibody Conjugates
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
SI2171090T1 (sl) * 2007-06-08 2013-07-31 Genentech, Inc. Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
KR101851580B1 (ko) 2007-07-09 2018-04-25 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
EP2474557B1 (en) 2007-07-16 2014-08-20 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
SG183044A1 (en) 2007-07-16 2012-08-30 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugatesand methods of use
KR20100075452A (ko) 2007-08-24 2010-07-02 온코세라피 사이언스 가부시키가이샤 전립선암 치료 및 진단의 표적 유전자로서의 ｐｋｉｂ 및 ｎａａｌａｄｌ２
CA2697513A1 (en) 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
WO2009028158A1 (en) 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
UA104715C2 (en) 2007-08-29 2014-03-11 Санофи-Авентис Isolated anti-cxcr5 antibody
JP6126773B2 (ja) 2007-09-04 2017-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原（ｐｓｃａ）抗体
PL2185574T3 (pl) 2007-09-07 2013-09-30 Agensys Inc Przeciwciała i powiązane cząsteczki, które wiążą się do białek 24P4C12
EP3059246B1 (en) 2007-09-26 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
EP2207805B1 (en) 2007-10-02 2014-07-09 Genentech, Inc. Nlrr-1 antagonists and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
DK2233149T3 (en) 2007-10-16 2016-05-17 Zymogenetics Inc COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE
RU2498991C2 (ru) 2007-10-30 2013-11-20 Дженентек, Инк. Очистка антител с помощью катионообменной хроматографии
JP5985150B2 (ja) 2007-11-07 2016-09-06 ジェネンテック， インコーポレイテッド 微生物障害の処置のための組成物および方法
CN104059143A (zh) 2007-11-12 2014-09-24 特罗科隆科学有限公司 用于对流行性感冒进行治疗以及诊断的组合物以及方法
WO2010135521A2 (en) 2009-05-20 2010-11-25 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
CA2706729A1 (en) 2007-11-29 2009-06-11 Genentech, Inc. Gene expression markers for inflammatory bowel disease
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
PT2222706E (pt) 2007-12-14 2014-07-28 Novo Nordisk As Anticorpos contra nkg2d humano e utilizações dos mesmos
US10416162B2 (en) 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
US8420620B2 (en) * 2008-01-24 2013-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Induced internalization of surface receptors
AU2009207644A1 (en) 2008-01-24 2009-07-30 Novo Nordisk A/S Humanized anti-human NKG2A monoclonal antibody
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
PL2247620T3 (pl) 2008-01-31 2017-08-31 Genentech, Inc. Przeciwciała anty-CD79B i immunokoniugaty i sposoby stosowania
AU2009213141A1 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
AU2009219437B2 (en) 2008-02-25 2014-10-16 Nestec S.A. Drug selection for breast cancer therapy using antibody-based arrays
US7982012B2 (en) 2008-03-10 2011-07-19 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus
KR102784999B1 (ko) 2008-03-18 2025-03-21 제넨테크, 인크. 항-ｈｅｒ２ 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법
ES2354661B1 (es) 2008-05-08 2012-02-01 Consejo Superior De Investigaciones Científicas (Csic) Método para generar anticuerpos monoclonales que reconocen antígenos de membrana de células progenitoras neurales, anticuerpos producidos por dicho método, y usos.
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
US20100029675A1 (en) * 2008-07-25 2010-02-04 Hwang Soo-In Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use
FI3604324T3 (fi) 2008-08-14 2024-05-16 Genentech Inc Menetelmiä epäpuhtauden poistamiseksi käyttäen luontaisen proteiinin syrjäytyksen ioninvaihtomembraanikromatografiaa
CN102282172B (zh) 2008-09-07 2014-02-19 台湾醣联生技医药股份有限公司 抗伸展的ⅰ型鞘糖脂抗体、其衍生物以及用途
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
CA2737597C (en) 2008-10-16 2017-03-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
JP5851838B2 (ja) 2008-10-22 2016-02-03 ジェネンテック， インコーポレイテッド 軸索変性の調節
US8734795B2 (en) 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
EP2358392B1 (en) 2008-11-12 2019-01-09 MedImmune, LLC Antibody formulation
AU2009313902B9 (en) 2008-11-13 2014-03-27 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation of BMP-6
CN102282168A (zh) * 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
BRPI0916138A2 (pt) 2008-11-22 2015-11-17 Genentech Inc "método de tratamento de um sujeito diagnosticado com câncer de mama localmente, kit para tratar câncer de mama metastático em um sujeito humano, uso de um anticorpo antivegf na fabricação de um medicamento para tratar câncer de mama localmente recidivado ou metastático em um sujeito e anticorpo anti-vegf para uso em um método de tratamento de câncer de mama localmente recidivado ou metastático em um sujeito"
US8211434B2 (en) 2008-11-26 2012-07-03 Allergan, Inc. KLK-13 antibody inhibitor for treating dry eye
SG177252A1 (en) 2008-12-01 2012-03-29 Lab Corp America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
MX2011005853A (es) 2008-12-09 2011-08-04 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
SG171764A1 (en) 2008-12-16 2011-07-28 Millipore Corp Purification of proteins
DK2370561T3 (da) 2008-12-16 2019-10-21 Emd Millipore Corp Omrøringstankreaktor og fremgangsmåde
JP2012512261A (ja) 2008-12-17 2012-05-31 ジェネンテック， インコーポレイテッド Ｃ型肝炎ウイルス併用療法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
ES2535723T3 (es) 2009-01-15 2015-05-14 Laboratory Corporation Of America Holdings Métodos de determinación de la respuesta del paciente mediante la medición de Her-3
CN102307875A (zh) 2009-02-09 2012-01-04 苏伯俭股份有限公司 吡咯并嘧啶基axl激酶抑制剂
CA2752510C (en) 2009-02-17 2024-01-23 Neil Bander Methods and kits for diagnosis of cancer and prediction of therapeutic value
WO2010095031A2 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010106535A1 (en) 2009-03-15 2010-09-23 Technion Research And Development Foundation Ltd. Soluble hla complexes for use in disease diagnosis
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
KR101362522B1 (ko) 2009-03-20 2014-02-14 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
ES2932874T3 (es) 2009-03-25 2023-01-27 Genentech Inc Anticuerpos anti-FGFR3 y métodos que utilizan los mismos
AU2010236787A1 (en) 2009-04-01 2011-11-10 Genentech, Inc. Anti-FcRH5 antibodies and immunoconjugates and methods of use
US20100266595A1 (en) 2009-04-01 2010-10-21 Kolumam Ganesh A Treatment of insulin-resistant disorders
HRP20150444T1 (hr) 2009-04-07 2015-05-22 Roche Glycart Ag Trovalentna, bispecifiäśna protutijela
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
US8753631B2 (en) * 2009-05-01 2014-06-17 New York University Therapeutic agents for inducing platelet fragmentation and treating thromboembolic disorders
EP2430451B1 (en) 2009-05-14 2014-08-13 The Chancellors, Masters and Scholars of the University of Oxford Clinical diagnosis of hepatic fibrosis / cirrhosis using low abundant human plasma protein biomarkers
BRPI1011206A2 (pt) 2009-05-25 2016-03-15 Merck Patent Gmbh administração contínua de ligantes de integrina para tratar câncer
EP2435071A1 (en) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
JP2012531418A (ja) 2009-06-23 2012-12-10 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体タンパク質に結合する二重特異性抗体
WO2011005715A1 (en) 2009-07-07 2011-01-13 Genentech, Inc. Diagnosis and treatment of autoimmune demyelinating diseases
CA2768013C (en) 2009-07-15 2018-08-21 Prometheus Laboratories Inc. Drug selection for gastric cancer therapy using antibody-based arrays
SG177699A1 (en) 2009-07-20 2012-02-28 Genentech Inc Gene expression markers for crohn's disease
AR077595A1 (es) 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
US20130017188A1 (en) 2009-07-31 2013-01-17 The Brigham And Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
WO2011014750A1 (en) 2009-07-31 2011-02-03 Genentech, Inc. Inhibition of tumor metastasis using bv8- or g-csf-antagonists
US20110039300A1 (en) 2009-08-10 2011-02-17 Robert Bayer Antibodies with enhanced adcc functions
MY186219A (en) 2009-08-11 2021-06-30 Genentech Inc Production of proteins in glutamine-free cell culture media
US20110038871A1 (en) 2009-08-11 2011-02-17 Veena Viswanth Ccr2 inhibitors for treating conditions of the eye
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
NZ598131A (en) 2009-08-15 2014-08-29 Genentech Inc Anti-angiogenesis therapy for the treatment of previously treated breast cancer
CA2772194A1 (en) 2009-09-01 2011-03-10 Pfizer Inc. Benzimidazole derivatives
RU2571929C2 (ru) 2009-09-01 2015-12-27 Дженентек, Инк. Улучшенная очистка белка посредством модифицированного элюирования белка а
AU2010289400B2 (en) 2009-09-02 2014-10-23 Curis, Inc. Mutant smoothened and methods of using the same
CN104945509A (zh) 2009-09-16 2015-09-30 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
DK2491385T3 (en) 2009-10-20 2017-08-28 Diatech Holdings Inc PROXIMITY-MEDIED ASSAYS FOR DETECTING ONCOGEN FUSION PROTEINS
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
BR112012009412A2 (pt) 2009-10-22 2016-11-29 Genentech Inc 'anticorpo anti-hepsina isolado, molécula de ácido nucleico, célula hospedeira, método para fabricar um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo e método para fabricar um anticorpo anti-serina protease'
CA2778483A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Modulation of axon degeneration
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
JP6007420B2 (ja) 2009-11-04 2016-10-12 ファブラス エルエルシー 親和性成熟に基づく抗体最適化方法
CA2780143A1 (en) 2009-11-05 2011-05-12 Genentech, Inc. Methods and composition for secretion of heterologous polypeptides
RU2015132142A (ru) 2009-11-30 2015-12-20 Дженентек, Инк. Композиции и способы для диагностики и лечения опухоли
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
RU2673908C2 (ru) 2009-12-02 2018-12-03 Имэджинэб, Инк. Мини-антитела j591 и цис-диатела для направленной доставки простата-специфичного мембранного антигена (psma) человека и способы их применения
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
EP2509626B1 (en) 2009-12-11 2016-02-10 F.Hoffmann-La Roche Ag Anti-vegf-c antibodies and methods using same
RU2609658C2 (ru) 2009-12-21 2017-02-02 Дженентек, Инк. Состав, содержащий антитело
ES2585350T3 (es) 2009-12-23 2016-10-05 F. Hoffmann-La Roche Ag Anticuerpos anti Bv8 y usos de los mismos
CN102781964B (zh) 2009-12-28 2015-11-25 肿瘤疗法科学股份有限公司 抗cdh3抗体及其用途
WO2011082187A1 (en) 2009-12-30 2011-07-07 Genentech, Inc. Methods for modulating a pdgf-aa mediated biological response
CN105001334A (zh) 2010-02-10 2015-10-28 伊缪诺金公司 Cd20抗体及其用途
PT2534153T (pt) 2010-02-12 2016-12-27 Pfizer Sais e polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
SG183333A1 (en) 2010-02-18 2012-09-27 Genentech Inc Neuregulin antagonists and use thereof in treating cancer
EP3696194A1 (en) 2010-02-23 2020-08-19 F. Hoffmann-La Roche AG Anti-angiogenesis therapy for the treatment of ovarian cancer
PE20130214A1 (es) 2010-02-23 2013-03-11 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
WO2011106222A2 (en) * 2010-02-23 2011-09-01 Corning Incorporated Modified substrates for protection of peptide-immobilized surfaces from gamma radiation degradation
EP2519826A2 (en) 2010-03-03 2012-11-07 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US9556248B2 (en) 2010-03-19 2017-01-31 The Board Of Trustees Of The Leland Stanford Junior University Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
KR101899835B1 (ko) 2010-03-24 2018-09-19 제넨테크, 인크. 항-ｌｒｐ６ 항체
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
CN102958941A (zh) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
JP5947289B2 (ja) 2010-05-10 2016-07-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗インフルエンザ活性を有するザナミビルホスホネート同族体およびインフルエンザウイルスのオセルタミビルに対する感受性の決定
SG184541A1 (en) 2010-05-17 2012-11-29 Emd Millipore Corp Stimulus responsive polymers for the purification of biomolecules
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
HRP20171095T4 (hr) 2010-05-25 2022-07-22 F. Hoffmann - La Roche Ag Postupci pročišćavanja polipeptida
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
PL2576580T3 (pl) 2010-05-28 2017-03-31 F.Hoffmann-La Roche Ag Zmniejszenie poziomu mleczanu i zwiększenie wytwarzania polipeptydu przez obniżenie poziomu ekspresji dehydrogenazy mleczanowej i kinazy dehydrogenazy pirogronianowej
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
MX336109B (es) 2010-06-03 2016-01-08 Genentech Inc Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
AU2011265054B2 (en) 2010-06-08 2016-09-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
ES2611479T3 (es) 2010-06-16 2017-05-09 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Anticuerpos contra endoplasmina y su uso
KR101885388B1 (ko) 2010-06-18 2018-08-03 제넨테크, 인크. 항-Ａｘｌ 항체 및 사용 방법
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
BR112013000340A2 (pt) 2010-07-09 2016-05-31 Genentech Inc anticorpo isolado que se liga a neuropilina-1 (nrp1), ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado e método de detecção da presença de nrp1 em uma amostra biológica
CN103153328A (zh) 2010-07-16 2013-06-12 默克专利股份有限公司 肽在乳腺癌和/或骨转移灶的治疗中的用途
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
SG187592A1 (en) 2010-07-23 2013-03-28 Univ Boston Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
EP2600895A1 (en) 2010-08-03 2013-06-12 Hoffmann-La Roche AG Chronic lymphocytic leukemia (cll) biomarkers
CN103209709A (zh) 2010-08-05 2013-07-17 弗·哈夫曼-拉罗切有限公司 抗mhc抗体抗病毒性细胞因子融合蛋白
AU2011289275A1 (en) 2010-08-12 2013-02-21 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
EP2420250A1 (en) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4 antibodies
TW201209063A (en) 2010-08-13 2012-03-01 Roche Glycart Ag Anti-tenascin-C A2 antibodies and methods of use
US9011847B2 (en) 2010-08-13 2015-04-21 Roche Glycart, AG Anti-FAP antibodies and methods of use
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
CN103080132B (zh) 2010-08-25 2016-06-08 弗·哈夫曼-拉罗切有限公司 抗il-18r1的抗体及其用途
RU2013114360A (ru) 2010-08-31 2014-10-10 Дженентек, Инк. Биомаркеры и способы лечения
CA3109036C (en) 2010-08-31 2023-08-01 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2012033953A1 (en) 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
JP5974012B2 (ja) 2010-10-05 2016-08-23 ジェネンテック， インコーポレイテッド 突然変異体スムースンド及びその使用方法
CA2813162C (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2- derivatives as smoothened receptor modulators
EP2633317A1 (en) 2010-10-25 2013-09-04 Genentech, Inc. Treatment of gastrointestinal inflammation and psoriasis a
WO2012064836A1 (en) 2010-11-10 2012-05-18 Genentech, Inc. Methods and compositions for neural disease immunotherapy
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
WO2012075333A2 (en) 2010-12-02 2012-06-07 Prometheus Laboratories Inc. Her2delta16 peptides
SG10201401746TA (en) 2010-12-16 2014-10-30 Genentech Inc Diagnosis And Treatments Relating To TH2 Inhibition
PH12018500046A1 (en) 2010-12-20 2019-04-08 Genentech Inc Anti-mesothelin antibodies and immunoconjugates
KR20130118925A (ko) 2010-12-22 2013-10-30 제넨테크, 인크. 항-pcsk9 항체 및 사용 방법
ES2656969T3 (es) 2010-12-23 2018-03-01 F. Hoffmann-La Roche Ag Detección de un dímero polipeptídico por un agente de unión bivalente
CN103384828A (zh) 2010-12-23 2013-11-06 雀巢产品技术援助有限公司 使用基于抗体的阵列进行恶性癌症疗法的药物选择
EP2659269B1 (en) 2010-12-23 2016-10-26 Roche Diagniostics GmbH Detection of a posttranslationally modified polypeptide by a bi-valent binding agent
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JP6162044B2 (ja) 2010-12-23 2017-07-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 結合剤
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US20120258073A1 (en) 2011-02-10 2012-10-11 Christian Gerdes Immunotherapy
DK2673294T3 (en) 2011-02-10 2016-05-30 Roche Glycart Ag MUTANT INTERLEUKIN-2 POLYPEPTIDES
CN103687619A (zh) 2011-02-14 2014-03-26 特罗科隆科学有限公司 用于对流行性感冒进行治疗以及诊断的组合物以及方法
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
KR101572338B1 (ko) 2011-02-28 2015-11-26 에프. 호프만-라 로슈 아게 1가 항원 결합 단백질
ES2549638T3 (es) 2011-02-28 2015-10-30 F. Hoffmann-La Roche Ag Proteínas de unión a antígeno
DK2681245T3 (en) 2011-03-03 2018-08-13 Zymeworks Inc MULTIVALENT HEAT-MULTIMED SCAFFOLD DESIGN AND CONSTRUCTIONS
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
JP2014518610A (ja) 2011-03-09 2014-08-07 リチャード ジー． ペステル 前立腺癌細胞系、遺伝子シグネチャー及びその使用
MX2013010367A (es) 2011-03-15 2014-04-14 Theraclone Sciences Inc Composiciones y metodos para la terapia y diagnostico de influenza.
US20130344074A1 (en) 2011-03-16 2013-12-26 Sanofi Uses of a dual v region antibody-like protein
KR101614195B1 (ko) 2011-03-29 2016-04-20 로슈 글리카트 아게 항체 Fc 변이체
CN103608038A (zh) 2011-03-31 2014-02-26 弗·哈夫曼-拉罗切有限公司 施用β7整联蛋白拮抗剂的方法
CN103596983B (zh) 2011-04-07 2016-10-26 霍夫曼-拉罗奇有限公司 抗fgfr4抗体及使用方法
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US20140178368A1 (en) 2011-04-19 2014-06-26 Leslie Lynne SHARP Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
AU2012244816B2 (en) 2011-04-20 2015-12-10 Roche Glycart Ag Method and constructs for the pH dependent passage of the blood-brain-barrier
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CN103608684B (zh) 2011-05-12 2016-05-04 基因泰克公司 利用框架签名肽检测动物样品中的治疗性抗体的多重反应监测lc-ms/ms方法
CA2834879C (en) 2011-05-16 2019-10-22 Genentech, Inc. Fgfr1 agonists and methods of use
RU2013158627A (ru) 2011-06-15 2015-07-20 Ф. Хоффманн-Ля Рош Аг Антитела к рецептору человеческого эритропоэтина и способы их применения
CA2835242A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
WO2013008171A1 (en) 2011-07-11 2013-01-17 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
JP6105578B2 (ja) 2011-07-21 2017-03-29 トレロ ファーマシューティカルズ， インコーポレイテッド 複素環式プロテインキナーゼ阻害剤
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
CN103890008A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 在顽固性肿瘤中抑制血管发生
US20140363438A1 (en) 2011-08-17 2014-12-11 Genentech, Inc. Neuregulin antibodies and uses thereof
BR112014003598B1 (pt) 2011-08-23 2022-05-31 Roche Glycart Ag Molécula de ligação de antígeno biespecífica, composição farmacêutica e uso da molécula de ligação de antígeno biespecífica
JP2014534806A (ja) 2011-08-23 2014-12-25 ロシュ グリクアート アーゲー 抗ｍｃｓｐ抗体
US20130078250A1 (en) 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
PT2748201T (pt) 2011-08-23 2018-02-08 Roche Glycart Ag Moléculas de ligação ao antigénio biespecíficas que ativam as células t
CA2844540C (en) 2011-08-23 2018-10-16 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
WO2013033069A1 (en) 2011-08-30 2013-03-07 Theraclone Sciences, Inc. Human rhinovirus (hrv) antibodies
ES2553456T3 (es) 2011-09-02 2015-12-09 Nestec S.A. Perfilado de proteínas de ruta de señal para determinar una eficacia terapéutica
GB201212550D0 (en) 2012-07-13 2012-08-29 Novartis Ag B cell assay
MX2014003094A (es) 2011-09-15 2014-04-25 Genentech Inc Metodos para promover diferenciacion.
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
WO2013043715A1 (en) 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
BR112014006840A2 (pt) 2011-09-22 2017-04-04 Pfizer derivados de pirrolopirimidina e purina
ES2654160T3 (es) 2011-10-04 2018-02-12 Igem Therapeutics Limited Anticuerpos de IgE anti-HMW-MAA
CA2849011A1 (en) 2011-10-05 2013-04-11 Genentech, Inc. Methods of treating liver conditions using notch2 antagonists
EP3461839A1 (en) 2011-10-14 2019-04-03 F. Hoffmann-La Roche AG Anti-htra1 antibodies and methods of use
BR112014008590A2 (pt) 2011-10-15 2017-10-24 Genentech Inc métodos de uso de antagonistas de scd1
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
WO2013063001A1 (en) 2011-10-28 2013-05-02 Genentech, Inc. Therapeutic combinations and methods of treating melanoma
SG11201402019TA (en) 2011-11-02 2014-09-26 Genentech Inc Overload and elute chromatography
CN104271599A (zh) 2011-11-08 2015-01-07 辉瑞公司 使用抗m-csf抗体治疗炎性疾病的方法
CN104066748A (zh) 2011-11-21 2014-09-24 霍夫曼-拉罗奇有限公司 抗c-met抗体的纯化
AU2012340623A1 (en) 2011-11-23 2014-07-17 Igenica Biotherapeutics, Inc. Anti-CD98 antibodies and methods of use thereof
AR089028A1 (es) 2011-11-29 2014-07-23 Genentech Inc Composiciones y metodos para el analisis de cancer de prostata
CN104271761B (zh) 2011-11-30 2017-03-15 霍夫曼-拉罗奇有限公司 癌症中的erbb3突变
WO2013083497A1 (en) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
PL2794651T3 (pl) 2011-12-22 2022-12-27 F.Hoffmann-La Roche Ag Kombinacje elementów wektora ekspresyjnego, nowe sposoby generowania komórek produkcyjnych i ich zastosowanie do rekombinowanej produkcji polipeptydów
SG11201403437TA (en) 2011-12-22 2014-07-30 Genentech Inc Ion exchange membrane chromatography
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
WO2013092723A1 (en) 2011-12-22 2013-06-27 F. Hoffmann-La Roche Ag Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
EP3663314A1 (en) 2012-01-09 2020-06-10 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
CN104520321A (zh) 2012-01-09 2015-04-15 斯克利普斯研究所 超长互补决定区及其用途
PE20141561A1 (es) 2012-01-18 2014-11-12 Genentech Inc Anticuerpos anti-lrp5 y metodos de uso
CA2862424A1 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
MX2014009043A (es) 2012-01-31 2014-10-14 Genentech Inc Anticuerpos anti-ige y sus metodos de uso.
WO2013113641A1 (en) 2012-01-31 2013-08-08 Roche Glycart Ag Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
WO2013119966A2 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
AU2013216753B2 (en) 2012-02-11 2017-09-21 Genentech, Inc. R-spondin translocations and methods using the same
WO2013120929A1 (en) 2012-02-15 2013-08-22 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
RU2014138586A (ru) 2012-03-02 2016-04-20 Рош Гликарт Аг Прогностический биомаркер для лечения рака антителами с повышенной антителозависимой клеточной цитотоксичностью
US20140170159A9 (en) 2012-03-08 2014-06-19 Ge Wei Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
KR20140148388A (ko) 2012-03-27 2014-12-31 제넨테크, 인크. Her3 억제제와 관련된 진단 및 치료
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
RU2014148162A (ru) 2012-05-01 2016-06-20 Дженентек, Инк. Анти-pmel17 антитела и их иммуноконъюгаты
CA2872540A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
AU2013262977A1 (en) 2012-05-14 2015-01-22 Prostagene, Llc Using modulators of CCR5 for treating cancer
EP3605090A1 (en) 2012-05-23 2020-02-05 F. Hoffmann-La Roche AG Selection method for therapeutic agents
JP2015520182A (ja) 2012-06-08 2015-07-16 グレンマーク ファーマシューティカルズ， エセ．アー． アミノ酸置換を有するヒト化抗ＴｒｋＡ抗体
CA2875096A1 (en) 2012-06-15 2013-12-19 Genentech, Inc. Anti-pcsk9 antibodies, formulations, dosing, and methods of use
CN104411718B (zh) 2012-06-27 2018-04-24 弗·哈夫曼-拉罗切有限公司 用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途
CN110256567B (zh) 2012-06-27 2023-04-25 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制靶向实体的方法及其用途
MX2014014065A (es) 2012-06-27 2015-02-04 Hoffmann La Roche Metodo para la seleccion y produccion de moleculas terapeuticas hechas a la medida, selectivas y multiespecificas que comprenden al menos dos diferentes entidades de direccionamiento y usos de las mismas.
HUE030858T2 (en) 2012-07-04 2017-06-28 Hoffmann La Roche Covalently linked antigen-antibody conjugates
CN104411725B (zh) 2012-07-04 2018-09-28 弗·哈夫曼-拉罗切有限公司 抗生物素抗体及使用方法
CN107082810B (zh) 2012-07-04 2020-12-25 弗·哈夫曼-拉罗切有限公司 抗茶碱抗体及使用方法
US9803191B2 (en) 2012-07-05 2017-10-31 Genentech, Inc. Expression and secretion system
WO2014011518A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Immunoconjugates comprising anti-cd22 antibodies
PE20150614A1 (es) 2012-07-09 2015-05-25 Genentech Inc Inmunoconjugados que comprenden un anticuerpo anti-cd79b ligado a un derivado de nemorrubicina
AR091701A1 (es) 2012-07-09 2015-02-25 Genentech Inc Anticuerpos anti-cd22 e inmunoconjugados
CN104540526A (zh) 2012-07-09 2015-04-22 基因泰克公司 包含抗cd79b抗体的免疫偶联物
WO2014012082A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Multivalent heteromultimer scaffold design an constructs
CN104428315B (zh) 2012-07-13 2017-09-29 罗氏格黎卡特股份公司 双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
AU2013301582B2 (en) 2012-08-07 2018-09-06 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
EA201500208A1 (ru) 2012-08-08 2015-07-30 Роше Гликарт Аг Слитые белки, содержащие интерлейкин-10, и их применения
MX2015001678A (es) 2012-08-09 2015-08-14 Roche Glycart Ag Anticuerpos asgpr y sus usos.
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
CA2883168A1 (en) 2012-08-21 2014-02-27 Academia Sinica Benzocyclooctyne compounds and uses thereof
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
EP2895496B1 (en) 2012-09-14 2017-06-07 F. Hoffmann-La Roche AG Method for the production and selection of molecules comprising at least two different entities and uses thereof
KR101850591B1 (ko) 2012-10-05 2018-04-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
JP6444874B2 (ja) 2012-10-08 2018-12-26 ロシュ グリクアート アーゲー ２つのＦａｂフラグメントを含むＦｃ不含抗体および使用方法
US20150231240A1 (en) 2012-10-09 2015-08-20 Igenica Biotherapeutics, Inc. Anti-c16orf54 antibodies and methods of use thereof
JP6243918B2 (ja) 2012-10-16 2017-12-06 トレロ ファーマシューティカルズ， インコーポレイテッド Ｐｋｍ２調節因子およびそれらの使用方法
WO2014071419A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
AR093378A1 (es) 2012-11-08 2015-06-03 Hoffmann La Roche PROTEINAS LIGANTES DE ANTIGENO HER3 DE UNION A LA HORQUILLA b DE HER3
KR20150083124A (ko) 2012-11-13 2015-07-16 제넨테크, 인크. 항-헤마글루티닌 항체 및 사용 방법
HK1217232A1 (zh) 2012-11-15 2016-12-30 F. Hoffmann-La Roche Ag 离子强度介导的ph梯度离子交换色谱
MX363188B (es) 2012-11-30 2019-03-13 Hoffmann La Roche Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
ES2689080T3 (es) 2013-01-02 2018-11-08 Glenmark Pharmaceuticals S.A. Anticuerpos que se unen a TL1A y sus usos
CA2898326C (en) 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
WO2014114595A1 (en) 2013-01-23 2014-07-31 Roche Glycart Ag Predictive biomarker for cancer treatment with adcc-enhanced antibodies
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
KR20150118159A (ko) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 암의 치료 방법 및 약물 내성의 예방 방법
LT2961771T (lt) 2013-02-26 2020-03-10 Roche Glycart Ag Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams
JP2016512421A (ja) 2013-02-26 2016-04-28 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
CN104936987A (zh) 2013-02-26 2015-09-23 罗切格利卡特公司 抗mcsp抗体
BR112015017800A2 (pt) 2013-02-26 2017-11-21 Roche Glycart Ag moléculas de ligação ao antígeno biespecífica ativadora de célula t, polinucleotídeo, polipeptídeo, vetor, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t
KR20150123250A (ko) 2013-03-06 2015-11-03 제넨테크, 인크. 암 약물 내성의 치료 및 예방 방법
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
MY199135A (en) 2013-03-13 2023-10-17 Genentech Inc Formulations with reduced oxidation
DK2968467T3 (da) 2013-03-13 2020-08-10 Hoffmann La Roche Formuleringer med reduceret oxidation
US10010611B2 (en) 2013-03-13 2018-07-03 Genentech, Inc. Antibody formulations
CA2905070A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
AU2014236820B2 (en) 2013-03-14 2018-08-02 Sumitomo Pharma Oncology, Inc. JAK2 and ALK2 inhibitors and methods for their use
WO2014152358A2 (en) 2013-03-14 2014-09-25 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
BR112015022019A2 (pt) 2013-03-14 2017-08-29 Genentech Inc Anticorpos isolados, ácido nucleico, célula hospedeira, método de produção de anticorpos, imunoconjugado, formulação farmacêutica, métodos de tratamento de indivíduos, de inibição da proliferação de células, de detecção de b7-h4 humano e de detecção de câncer
RU2015144020A (ru) 2013-03-15 2017-04-21 Дженентек, Инк. Среды для культивирования клеток и способы получения антител
US20140328849A1 (en) 2013-03-15 2014-11-06 Genentech, Inc. Anti-crth2 antibodies and methods of use
KR20150131269A (ko) 2013-03-15 2015-11-24 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
WO2014150877A2 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
EP2968537A1 (en) 2013-03-15 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
EP2970875B2 (en) 2013-03-15 2025-11-26 F. Hoffmann-La Roche AG Cell culture compositions with antioxidants and methods for polypeptide production
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
AU2014236815B2 (en) 2013-03-15 2019-04-04 Genentech, Inc. Compositions and methods for diagnosis and treatment of hepatic cancers
PE20160690A1 (es) 2013-03-18 2016-08-14 Biocerox Prod Bv Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos
SG11201507974RA (en) 2013-03-27 2015-10-29 Genentech Inc Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
EP2983710B1 (en) 2013-04-09 2019-07-31 Annexon, Inc. Methods of treatment for neuromyelitis optica
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
WO2014182970A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
HRP20240107T1 (hr) 2013-05-20 2024-04-12 F. Hoffmann - La Roche Ag Protutijela na transferinski receptor i postupci uporabe
EP3004068A2 (en) 2013-05-24 2016-04-13 Nestec S.A. Pathway specific assays for predicting irritable bowel syndrome diagnosis
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
SI3019240T1 (sl) 2013-07-09 2024-07-31 Annexon, Inc. Protitelesa proti komplementnemu faktorju C1q in njihova uporaba
EP3536699A1 (en) 2013-07-12 2019-09-11 F. Hoffmann-La Roche AG Elucidation of ion exchange chromatography input optimization
ES2964893T3 (es) * 2013-07-17 2024-04-10 Found Medicine Inc Procedimientos de tratamiento de carcinomas uroteliales
WO2015010100A2 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
CA2922832A1 (en) 2013-09-05 2015-03-12 Genentech, Inc. Method for chromatography reuse
EP3041484B1 (en) 2013-09-06 2021-03-03 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
AU2014318545A1 (en) 2013-09-12 2016-03-24 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2015038884A2 (en) 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
CA3184564A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Methods and compositions comprising an anti-il13 antibody and residual hamster phospholipase b-like 2
CA2924286C (en) 2013-09-17 2022-06-21 Obi Pharma, Inc. Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
CN105518027A (zh) 2013-09-17 2016-04-20 豪夫迈·罗氏有限公司 使用抗lgr5抗体的方法
ES2768614T3 (es) 2013-09-27 2020-06-23 Hoffmann La Roche Formulaciones de anticuerpos anti-PDL1
WO2015044083A1 (en) 2013-09-27 2015-04-02 F. Hoffmann-La Roche Ag Thermus thermophilus slyd fkbp domain specific antibodies
KR20160058960A (ko) 2013-10-04 2016-05-25 압토스 바이오사이언시스 인코포레이티드 암을 치료하기 위한 조성물과 방법
KR20160068855A (ko) 2013-10-11 2016-06-15 제넨테크, 인크. Nsp4 억제제 및 사용 방법
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
JP6677638B2 (ja) 2013-10-18 2020-04-08 ジェネンテック， インコーポレイテッド 抗ｒｓｐｏ２及び／又はｒｓｐｏ３抗体及びそれらの使用
CN105849280B (zh) 2013-10-23 2020-11-06 豪夫迈·罗氏有限公司 诊断和治疗嗜酸性粒细胞紊乱的方法
AU2014348552A1 (en) 2013-11-13 2016-06-02 Zymeworks Inc. Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
KR102358311B1 (ko) 2013-11-21 2022-02-08 에프. 호프만-라 로슈 아게 항-알파-시누클레인 항체 및 사용 방법
HRP20250551T1 (hr) 2013-11-27 2025-06-20 Zymeworks Bc Inc. Bispecifični antigen-vezujući konstrukti koji ciljaju her2
CN114044825A (zh) 2013-12-09 2022-02-15 爱乐科斯公司 抗Siglec-8抗体及其使用方法
SG11201604784XA (en) 2013-12-13 2016-07-28 Genentech Inc Anti-cd33 antibodies and immunoconjugates
HRP20240939T1 (hr) 2013-12-17 2024-10-25 Genentech, Inc. Anti-cd3 protutijela i metode uporabe
US20150210772A1 (en) 2013-12-17 2015-07-30 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
CN112353943A (zh) 2013-12-17 2021-02-12 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂和紫杉烷治疗癌症的方法
JP2017501167A (ja) 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
WO2015091656A1 (en) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
JP6602304B2 (ja) 2014-01-03 2019-11-06 エフ．ホフマン−ラ ロシュ アーゲー 共有結合で連結されたヘリカー−抗ヘリカー抗体コンジュゲートおよびその用途
US10561737B2 (en) 2014-01-03 2020-02-18 Hoffmann-La Roche Inc. Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
EP3089759B1 (en) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Covalently linked polypeptide toxin-antibody conjugates
CN105873947A (zh) 2014-01-06 2016-08-17 豪夫迈·罗氏有限公司 单价血脑屏障穿梭模块
CN105899538A (zh) 2014-01-10 2016-08-24 博笛生物科技（北京）有限公司 靶向her2阳性肿瘤的化合物和组合物
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
TW201620939A (zh) 2014-01-16 2016-06-16 中央研究院 治療及檢測癌症之組合物及方法
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
AU2015209154A1 (en) 2014-01-24 2017-02-16 Genentech, Inc. Methods of using anti-STEAP1 antibodies and immunoconjugates
UA119863C2 (uk) 2014-01-24 2019-08-27 Нгм Біофармасьютікалс, Інк. Антитіло або його фрагмент, що зв'язується з бета-клото
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
US20170044232A1 (en) 2014-02-04 2017-02-16 Genentech, Inc. Mutant smoothened and methods of using the same
SG11201606490YA (en) 2014-02-08 2016-09-29 Genentech Inc Methods of treating alzheimer's disease
CA2938466C (en) 2014-02-08 2021-11-02 Genentech, Inc. Methods of treating alzheimer's disease
RS57608B1 (sr) 2014-02-12 2018-11-30 Hoffmann La Roche Anti-jagged1 antitela i načini primene
EP3107574A2 (en) 2014-02-21 2016-12-28 F. Hoffmann-La Roche AG Anti-il-13/il-17 bispecific antibodies and uses thereof
US10183996B2 (en) 2014-02-28 2019-01-22 Allakos Inc. Methods and compositions for treating Siglec-8 associated diseases
HRP20192346T1 (hr) 2014-03-14 2020-03-20 Novartis Ag Molekule anti-lag-3 antitijela i njihove uporabe
BR112016020822A2 (pt) 2014-03-14 2017-10-03 Genentech Inc Métodos e composições para secreção de polipeptídeos heterólogos
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
CA2938722A1 (en) 2014-03-21 2015-09-24 F. Hoffmann-La Roche Ag In vitro prediction of in vivo half-life of antibodies
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
CA2943329A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
JP6562942B2 (ja) 2014-03-27 2019-08-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 反応性標識化合物およびその使用
RU2016136716A (ru) 2014-03-27 2018-04-28 Дженентек, Инк. Способы диагностики и лечения воспалительного заболевания кишечника
JP6637439B2 (ja) 2014-03-31 2020-01-29 ジェネンテック， インコーポレイテッド 抗ｏｘ４０抗体及び使用方法
EP3126386A1 (en) 2014-03-31 2017-02-08 F. Hoffmann-La Roche AG Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
EP3808778A1 (en) 2014-04-18 2021-04-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
JP6792454B2 (ja) 2014-04-25 2020-11-25 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． アルファ−フェトプロテイン（ａｆｐ）を操作するための方法
EA033919B1 (ru) 2014-04-30 2019-12-10 Пфайзер Инк. Соединённые циклоалкилом дигетероциклические производные
US10179821B2 (en) 2014-05-01 2019-01-15 Genentech, Inc. Anti-factor D antibodies
CN106415269B (zh) 2014-05-08 2020-11-27 贵州美鑫达医疗科技有限公司 直接免疫组织化学测定
CA2946662A1 (en) 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
MX2016015163A (es) 2014-05-23 2017-03-03 Genentech Inc Biomarcadores mit y metodos para su uso.
TWI670078B (zh) 2014-05-27 2019-09-01 中央研究院 抗ｃｄ２０醣抗體及其用途
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR102576850B1 (ko) 2014-05-27 2023-09-11 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
CA2950440A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-her2 glycoantibodies and uses thereof
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
BR112016028838A2 (pt) 2014-06-11 2017-10-24 Genentech Inc anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer
CN107135646B (zh) 2014-06-13 2022-03-15 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
EP3154589A1 (en) 2014-06-13 2017-04-19 Genentech, Inc. Methods of treating and preventing cancer drug resistance
MX384037B (es) 2014-06-26 2025-03-14 Hoffmann La Roche Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
EP3164194B1 (en) 2014-07-03 2021-11-24 Yale University Dickkopf2 (dkk2) inhibition suppresses tumor formation
WO2016004370A1 (en) 2014-07-03 2016-01-07 Genentech, Inc. Polypeptide expression systems
CN112546230A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
WO2016004876A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
CN106488775A (zh) 2014-07-11 2017-03-08 基因泰克公司 Notch途径抑制
JP7032929B2 (ja) 2014-07-11 2022-03-09 ヴェンタナ メディカル システムズ， インク． 抗ｐｄ－ｌ１抗体及びその診断上の使用
EP3722316A1 (en) 2014-07-21 2020-10-14 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
SG11201700476VA (en) 2014-07-21 2017-02-27 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
PE20211533A1 (es) 2014-08-04 2021-08-16 Hoffmann La Roche Moleculas biespecificas de unon a antigeno activadoras de celulas t
EA201790342A1 (ru) 2014-08-08 2017-07-31 ЭЛЕКТОР ЭлЭлСи Антитела к trem2 и способы их применения
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
MX2017002205A (es) 2014-08-19 2017-08-21 Novartis Ag Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
DK3186281T3 (da) 2014-08-28 2019-06-11 Halozyme Inc Kombinationsterapi med et hyaluronan-nedbrydende enzym og en immun-checkpoint-inhibitor
DK3186284T3 (da) 2014-08-28 2022-05-09 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
KR102422375B1 (ko) 2014-09-08 2022-07-18 아카데미아 시니카 당지질을 사용한 인간 iNKT 세포 활성화
PE20170935A1 (es) 2014-09-12 2017-07-13 Genentech Inc Anticuerpos anti-her2 e inmunoconjugados
WO2016040724A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
TW201625688A (zh) 2014-09-12 2016-07-16 建南德克公司 經半胱胺酸改造之抗體及接合物
TW201625690A (zh) 2014-09-12 2016-07-16 建南德克公司 抗－ｃｌｌ－１抗體及免疫結合物
CA2959545A1 (en) 2014-09-15 2016-03-24 Genentech, Inc. Antibody formulations
CA2957148A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
EP3967709A1 (en) 2014-09-17 2022-03-16 Novartis AG Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US20160082120A1 (en) 2014-09-23 2016-03-24 Genentech, Inc. METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
EP3197495A4 (en) 2014-09-28 2018-08-29 The Regents of The University of California Modulation of stimulatory and non-stimulatory myeloid cells
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
CN107074938A (zh) 2014-10-16 2017-08-18 豪夫迈·罗氏有限公司 抗‑α‑突触核蛋白抗体和使用方法
AU2015343339A1 (en) 2014-11-03 2017-06-15 Genentech, Inc. Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment
AU2015343337A1 (en) 2014-11-03 2017-06-15 Genentech, Inc. Assays for detecting T cell immune subsets and methods of use thereof
EP3753948A1 (en) 2014-11-05 2020-12-23 Genentech, Inc. Methods of producing two chain proteins in bacteria
US10316081B2 (en) 2014-11-05 2019-06-11 Annexon, Inc. Humanized anti-complement factor C1Q antibodies
MX2017003478A (es) 2014-11-05 2018-02-01 Genentech Inc Anticuerpos anti-fgfr2/3 y metodos para su uso.
RU2705274C2 (ru) 2014-11-05 2019-11-06 Дженентек, Инк. Способы получения двуцепочечных белков в бактериях
CA2963974A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
SG11201703767XA (en) 2014-11-10 2017-06-29 Genentech Inc Anti-interleukin-33 antibodies and uses thereof
JP2018500882A (ja) 2014-11-10 2018-01-18 ジェネンテック， インコーポレイテッド 腎症の動物モデルおよびそれを治療するための薬剤
RS61870B1 (sr) 2014-11-14 2021-06-30 Hoffmann La Roche Antigen vezujući molekuli koji sadrže trimer liganda iz tnf familije
US20160166685A1 (en) 2014-11-17 2016-06-16 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CN107257805A (zh) 2014-11-19 2017-10-17 雀巢产品技术援助有限公司 抗血清素、色氨酸和犬尿氨酸代谢产物的抗体及其用途
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
US10508151B2 (en) 2014-11-19 2019-12-17 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
EP3845565A3 (en) 2014-11-19 2021-09-08 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
EP3221356B1 (en) 2014-11-20 2020-09-02 F.Hoffmann-La Roche Ag T cell activating bispecific antigen binding molecules against folr1 and cd3
PT3221357T (pt) 2014-11-20 2020-07-28 Hoffmann La Roche Cadeias leves comuns e métodos de utilização
HUE067988T2 (hu) 2014-11-20 2024-12-28 Hoffmann La Roche T-sejteket aktiváló bispecifikus antigénkötõ molekulák és PD-1 tengelyt célzó antagonisták kombinációs terápiája
JP6872482B2 (ja) 2014-11-27 2021-05-19 ザイムワークス，インコーポレイテッド Ｈｅｒ２を標的とする二重特異性抗原結合性構築物の使用方法
WO2016087514A1 (en) 2014-12-02 2016-06-09 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
PL3227332T3 (pl) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
HUE045216T2 (hu) 2014-12-05 2019-12-30 Hoffmann La Roche Anti-CD79B antitestek és alkalmazási eljárások
SG11201703750XA (en) 2014-12-10 2017-06-29 Genentech Inc Blood brain barrier receptor antibodies and methods of use
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
JP6621477B2 (ja) 2014-12-18 2019-12-18 ファイザー・インク ピリミジンおよびトリアジン誘導体ならびにａｘｌ阻害薬としてのそれらの使用
EP3034130B1 (en) 2014-12-19 2019-12-04 Althia Health, S.L. Monoclonal antibody for the diagnosis, treatment and/or prevention of brain tumors and brain lesions
WO2016098357A1 (en) 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
TWI725847B (zh) 2014-12-19 2021-04-21 日商中外製藥股份有限公司 抗c5抗體及使用方法
AU2016206682B2 (en) 2015-01-14 2021-11-11 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-LAP monoclonal antibodies
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
JP2018511557A (ja) 2015-01-22 2018-04-26 中外製薬株式会社 ２種以上の抗ｃ５抗体の組み合わせおよび使用方法
CA2972731A1 (en) 2015-01-24 2016-07-28 Chi-Huey Wong Cancer markers and methods of use thereof
JP6779887B2 (ja) 2015-01-24 2020-11-04 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 新規なグリカンコンジュゲートおよびその使用方法
JP2018506275A (ja) 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
CA2973886A1 (en) 2015-01-30 2016-08-04 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CN107636170A (zh) 2015-02-04 2018-01-26 健泰科生物技术公司 突变型Smoothened及其使用方法
AU2016216079A1 (en) 2015-02-05 2017-07-13 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, Fc region variants, IL-8-binding antibodies, and uses therof
EP3262064A1 (en) 2015-02-23 2018-01-03 Seagull Therapeutics SAS Non-natural semaphorins 3 and their medical use
AU2016222683A1 (en) 2015-02-26 2017-07-13 Genentech, Inc. Integrin beta7 antagonists and methods of treating crohn's disease
AR103852A1 (es) 2015-03-06 2017-06-07 Genentech Inc DsbA Y DsbC ULTRAPURIFICADOS Y SUS MÉTODOS DE PREPARACIÓN Y USO
WO2016149276A1 (en) 2015-03-16 2016-09-22 Genentech, Inc. Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
CN107614020A (zh) 2015-03-18 2018-01-19 免疫生化公司 靶向细胞内肿瘤相关抗原的用于治疗癌症的缀合物
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
BR112017021510A2 (pt) 2015-04-06 2018-07-03 Acceleron Pharma Inc heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
AU2016246695A1 (en) 2015-04-07 2017-10-26 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
MX393951B (es) 2015-04-07 2025-03-24 Alector Llc Anticuerpos antisortilina y métodos para su uso.
BR112017021500A2 (pt) 2015-04-08 2018-09-25 Novartis Ag terapias com cd20, terapias com cd22 e terapias de combinação com uma célula que expressa (car) receptor de antígeno quimérico de cd19
JP6851978B2 (ja) 2015-04-20 2021-03-31 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ミトコンドリアプロファイリングによるアルボシジブ応答の予測
CN113552350B (zh) 2015-04-21 2024-10-11 基因泰克公司 用于前列腺癌分析的组合物和方法
GB201506870D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
JP7044553B2 (ja) 2015-04-24 2022-03-30 ジェネンテック， インコーポレイテッド 結合ポリペプチドを含む細菌を特定する方法
WO2016179003A1 (en) 2015-05-01 2016-11-10 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
US10011629B2 (en) 2015-05-01 2018-07-03 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
WO2016183104A1 (en) 2015-05-11 2016-11-17 Genentech, Inc. Compositions and methods of treating lupus nephritis
HUE051815T2 (hu) 2015-05-12 2021-03-29 Hoffmann La Roche Terápiás és diagnosztikai eljárások rákra
TR201911032T4 (tr) 2015-05-18 2019-08-21 Tolero Pharmaceuticals Inc Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları.
MX392706B (es) 2015-05-28 2025-03-24 Genentech Inc Ensayo a base de células para detectar homodímeros anti-cd3.
CA2984003A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
CN107771182A (zh) 2015-05-29 2018-03-06 豪夫迈·罗氏有限公司 人源化抗埃博拉病毒糖蛋白抗体和使用方法
AR105618A1 (es) 2015-05-29 2017-10-25 Genentech Inc Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer
KR20180011117A (ko) 2015-05-31 2018-01-31 큐어제닉스 코포레이션 면역 요법용 복합 조성물
HK1249016A1 (zh) 2015-06-02 2018-10-26 豪夫迈‧罗氏有限公司 使用抗il-34抗体治疗神经疾病的组合物和方法
US10112990B2 (en) 2015-06-05 2018-10-30 Genentech, Inc. Anti-Tau antibodies and methods of use
MX2017015937A (es) 2015-06-08 2018-12-11 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
CN107810011A (zh) 2015-06-08 2018-03-16 豪夫迈·罗氏有限公司 使用抗ox40抗体治疗癌症的方法
US11174313B2 (en) 2015-06-12 2021-11-16 Alector Llc Anti-CD33 antibodies and methods of use thereof
CN107922480B (zh) 2015-06-12 2022-09-23 艾利妥 抗cd33抗体及其使用方法
EP3307780A1 (en) 2015-06-15 2018-04-18 Genentech, Inc. Antibodies and immunoconjugates
FI3310814T3 (fi) 2015-06-16 2023-09-21 Hoffmann La Roche HUMANISOITUJA JA AFFINITEETTIKYPSIÄ FcRH5-VASTA-AINEITA JA KÄYTTÖMENETELMIÄ
CN107847568B (zh) 2015-06-16 2022-12-20 豪夫迈·罗氏有限公司 抗cll-1抗体和使用方法
JP2018526972A (ja) 2015-06-16 2018-09-20 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体及び使用方法
US10774145B2 (en) 2015-06-17 2020-09-15 Allakos Inc. Methods and compositions for treating fibrotic diseases
CN107787331B (zh) 2015-06-17 2022-01-11 豪夫迈·罗氏有限公司 抗her2抗体和使用方法
CN116327953A (zh) 2015-06-17 2023-06-27 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
PL3313877T3 (pl) 2015-06-24 2020-11-02 F. Hoffmann-La Roche Ag Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania
MX2017016645A (es) 2015-06-29 2018-11-09 Genentech Inc Anticuerpo anti-cd20 de tipo ii para su uso en el trasplante de órganos.
WO2017001350A1 (en) 2015-06-29 2017-01-05 Ventana Medical Systems, Inc. Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
HUE055469T2 (hu) 2015-07-29 2021-11-29 Novartis Ag A LAG-3 elleni antitest molekulákat tartalmazó kombinált terápiák
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
BR112018002427A8 (pt) 2015-08-03 2022-10-18 Tolero Pharmaceuticals Inc Uso de alvocidib e de azacitidina ou decitabina para tratar câncer e kit e composição farmacêutica contendo as ditas substâncias
EP3331550B1 (en) 2015-08-04 2022-11-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
TW202440904A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（二）
EP4137158A1 (en) 2015-08-07 2023-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP3932953A1 (en) 2015-08-28 2022-01-05 F. Hoffmann-La Roche AG Anti-hypusine antibodies and uses thereof
KR20180054639A (ko) 2015-08-28 2018-05-24 알렉터 엘엘씨 항-siglec-7 항체 및 이의 사용 방법
KR20180050339A (ko) 2015-09-04 2018-05-14 오비아이 파머 인코퍼레이티드 글리칸 어레이 및 사용 방법
JP2018528218A (ja) 2015-09-11 2018-09-27 アンドリアン、ブルース 組換えグリコシル化エクリズマブおよびエクリズマブ変異体
TW202342532A (zh) 2015-09-18 2023-11-01 日商中外製藥股份有限公司 Il-8結合抗體及其用途
AU2016328357B2 (en) 2015-09-22 2023-03-02 Ventana Medical Systems, Inc. Anti-OX40 antibodies and diagnostic uses thereof
MA42924A (fr) 2015-09-23 2018-08-01 Hoffmann La Roche Variants optimisés d'anticorps anti-vegf
KR20220104289A (ko) 2015-09-25 2022-07-26 제넨테크, 인크. 항-tigit 항체 및 이의 이용 방법
WO2017058881A1 (en) 2015-09-28 2017-04-06 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
HK1251158A1 (zh) 2015-09-29 2019-01-25 细胞基因公司 Pd-1结合蛋白及其使用方法
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
US20180282410A1 (en) 2015-10-02 2018-10-04 Hoffmann-La Roche Inc. Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
WO2017055385A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
CR20180162A (es) 2015-10-02 2018-05-25 Hoffmann La Roche Moléculas biespecíficas de unión a antígeno activadoras de células t
WO2017055392A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
EP3356407B1 (en) 2015-10-02 2021-11-03 F. Hoffmann-La Roche AG Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
US20170096485A1 (en) 2015-10-02 2017-04-06 Hoffmann-La Roche Inc. Bispecific t cell activating antigen binding molecules
RS62450B1 (sr) 2015-10-02 2021-11-30 Hoffmann La Roche Anti-pd1 antitela i postupci primene
HK1254068A1 (zh) 2015-10-02 2019-07-12 豪夫迈‧罗氏有限公司 双特异性t细胞活化性抗原结合分子
SI3356411T1 (sl) 2015-10-02 2021-09-30 F. Hoffmann-La Roche Ag Bispecifična protitelesa, specifična za PD1 in TIM3
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
WO2017055393A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
CN115594765A (zh) 2015-10-02 2023-01-13 豪夫迈·罗氏有限公司（Ch） 对共刺激性tnf受体特异性的双特异性抗体
KR20180075537A (ko) 2015-10-06 2018-07-04 제넨테크, 인크. 다발성 경화증을 치료하기 위한 방법
KR20180068999A (ko) 2015-10-06 2018-06-22 알렉터 엘엘씨 항-trem2 항체 및 그의 사용방법
US11203634B2 (en) 2015-10-07 2021-12-21 Alexion Pharmaceuticals, Inc. Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody
WO2017060144A1 (en) 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory tnf receptor
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
EP3365442B8 (en) 2015-10-23 2022-06-08 Fred Hutchinson Cancer Center Methods to create chemically-induced dimerizing protein systems for regulation of cellular events
AU2016344459B2 (en) 2015-10-28 2023-10-05 Yale University Humanized anti-DKK2 antibody and uses thereof
AU2016343987B2 (en) 2015-10-29 2023-11-23 Alector Llc Anti-Siglec-9 antibodies and methods of use thereof
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
AU2016344665C1 (en) 2015-10-29 2023-07-27 F. Hoffmann-La Roche Ag Anti-variant Fc-region antibodies and methods of use
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
RU2021117293A (ru) 2015-10-30 2021-06-23 Дженентек, Инк. АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
EP3370754A4 (en) 2015-11-04 2019-10-23 Acceleron Pharma Inc. METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE
EP4671281A2 (en) 2015-11-08 2025-12-31 F. Hoffmann-La Roche AG MULTISPECIFIC ANTIBODY SCREENING METHODS
KR20180096645A (ko) 2015-11-23 2018-08-29 악셀레론 파마 인코포레이티드 눈 질환의 치료 방법
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
JP6877429B2 (ja) 2015-12-03 2021-05-26 アジオス ファーマシューティカルズ， インコーポレイテッド Ｍｔａｐヌル癌を処置するためのｍａｔ２ａ阻害剤
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
BR112018003984A2 (pt) 2015-12-09 2018-09-25 Hoffmann La Roche anticorpos
MY196200A (en) 2015-12-15 2023-03-22 Gilead Sciences Inc Human Immunodeficiency Virus Neutralizing Antibodies
RU2018125603A (ru) 2015-12-17 2020-01-21 Новартис Аг Комбинация ингибитора с-мет с молекулой антитела к pd-1 и ее применения
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
TWI868415B (zh) 2015-12-18 2025-01-01 日商中外製藥股份有限公司 抗肌抑素抗體、含變異fc區之多肽及使用方法
UA123774C2 (uk) 2015-12-18 2021-06-02 Чугаі Сейяку Кабусікі Кайся Антитіла проти c5 та способи застосування
WO2017112741A1 (en) 2015-12-22 2017-06-29 Novartis Ag Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
KR20250052501A (ko) 2015-12-30 2025-04-18 제넨테크, 인크. 분해가 감소된 폴리소르베이트를 갖는 제형
WO2017117304A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Use of tryptophan derivatives for protein formulations
JP2019509714A (ja) 2016-01-05 2019-04-11 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． Ｐｃｓｋ９抗体、その抗原結合フラグメント及び医薬用途
AU2017205089B2 (en) 2016-01-08 2023-10-05 F. Hoffmann-La Roche Ag Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
WO2017127764A1 (en) 2016-01-20 2017-07-27 Genentech, Inc. High dose treatments for alzheimer's disease
MA55746A (fr) 2016-01-21 2022-03-02 Novartis Ag Molécules multispécifiques ciblant cll-1
US11513127B2 (en) 2016-01-25 2022-11-29 Genentech, Inc. Methods for assaying T-cell dependent bispecific antibodies
EP3411396A1 (en) 2016-02-04 2018-12-12 Curis, Inc. Mutant smoothened and methods of using the same
US10982136B2 (en) 2016-02-26 2021-04-20 The Regents Of The University Of California Ligand-sensitized lanthanide nanocrystals as ultraviolet downconverters
KR102500659B1 (ko) 2016-02-29 2023-02-16 제넨테크, 인크. 암에 대한 치료 및 진단 방법
WO2017149515A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
WO2017152102A2 (en) 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
EP3216458A1 (en) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modified vascular endothelial growth factor a (vegf-a) and its medical use
TW201808978A (zh) 2016-03-08 2018-03-16 中央研究院 N-聚醣及其陣列之模組化合成方法
CN109153719B (zh) 2016-03-15 2022-12-30 中外制药株式会社 使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
KR102444614B1 (ko) 2016-03-22 2022-09-21 에프. 호프만-라 로슈 아게 프로테아제-활성화된 t 세포 이중특이적 분자
HRP20230528T1 (hr) 2016-03-22 2023-08-04 F. Hoffmann - La Roche Ag Bispecifične molekule t stanica aktivirane proteazom
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
TWI780045B (zh) 2016-03-29 2022-10-11 台灣浩鼎生技股份有限公司 抗體、醫藥組合物及方法
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
WO2017177013A1 (en) 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
US20170319688A1 (en) 2016-04-14 2017-11-09 Genentech, Inc. Anti-rspo3 antibodies and methods of use
AU2017248766A1 (en) 2016-04-15 2018-11-01 Genentech, Inc. Methods for monitoring and treating cancer
KR102459684B1 (ko) 2016-04-15 2022-10-26 바이오아트라, 인코퍼레이티드 항 Axl항체 및 이의 면역접합체와 이것들의 용도
ES2850428T3 (es) 2016-04-15 2021-08-30 Hoffmann La Roche Procedimientos de monitorización y tratamiento del cáncer
EP4219721A3 (en) 2016-04-15 2023-09-06 Novartis AG Compositions and methods for selective protein expression
MY200886A (en) 2016-04-22 2024-01-22 Obi Pharma Inc Cancer Immunotherapy by Immune Activation or Immune Modulation Via Globo Series Antigens
RU2018141360A (ru) 2016-05-02 2020-06-03 Ф. Хоффманн-Ля Рош Аг Contorsbody - одноцепочечный связывающий мишень агент
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CN109071652B (zh) 2016-05-11 2022-09-23 豪夫迈·罗氏有限公司 包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
WO2017194441A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Modified anti-tenascin antibodies and methods of use
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
EP3455261B1 (en) 2016-05-13 2022-08-03 BioAtla, Inc. Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
KR20190007026A (ko) 2016-05-17 2019-01-21 제넨테크, 인크. 면역요법에서의 진단 및 사용을 위한 기질 유전자 특질
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
WO2017210617A2 (en) 2016-06-02 2017-12-07 Porter, David, L. Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
US10851159B2 (en) 2016-06-02 2020-12-01 Bloom Diagnostics Ag Antibodies that bind to human anti-Müllerian hormone (AMH) and their uses
TW201902512A (zh) 2016-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 治療方法
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
MX2018015173A (es) 2016-06-17 2019-07-04 Genentech Inc Purificacion de anticuerpos multiespecificos.
CN109311969B (zh) 2016-06-17 2022-09-27 中外制药株式会社 抗-肌肉生长抑制因子抗体及使用方法
JP7133477B2 (ja) 2016-06-24 2022-09-08 ジェネンテック， インコーポレイテッド 抗ポリユビキチン多重特異性抗体
WO2018011691A1 (en) 2016-07-12 2018-01-18 Nestec S.A. Competitive immunoassay methods
US20190233534A1 (en) 2016-07-14 2019-08-01 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
MX378869B (es) 2016-07-15 2025-03-10 Acceleron Pharma Inc Composiciones y metodos para tratar hipertension pulmonar.
US20190336504A1 (en) 2016-07-15 2019-11-07 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
TWI752988B (zh) 2016-07-27 2022-01-21 台灣浩鼎生技股份有限公司 免疫性/治療性聚醣組合物及其用途
EA201990226A1 (ru) 2016-07-27 2019-08-30 Акселерон Фарма Инк. Способы и композиции для лечения миелофиброза
JP2019523301A (ja) 2016-07-28 2019-08-22 ノバルティス アーゲー キメラ抗原受容体とｐｄ−１阻害薬との併用療法
JP7121724B2 (ja) 2016-07-29 2022-08-18 オービーアイ ファーマ，インコーポレイテッド ヒト抗体、医薬組成物及び方法
BR112019001179A2 (pt) 2016-07-29 2019-04-30 Chugai Seiyaku Kabushiki Kaisha anticorpo biespecífico que exibe atividade alternativa aumentada de função de cofator fviii
WO2018026819A2 (en) 2016-08-01 2018-02-08 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
US11046776B2 (en) 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
KR102538749B1 (ko) 2016-08-05 2023-06-01 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
JP7093767B2 (ja) 2016-08-11 2022-06-30 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
AU2017312540B2 (en) 2016-08-15 2023-02-02 Genentech, Inc. Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
KR102588027B1 (ko) 2016-08-22 2023-10-12 초 파마 인크. 항체, 결합 단편 및 사용 방법
ES3015117T3 (en) 2016-08-29 2025-04-29 Fred Hutchinson Cancer Center Chelating platform for delivery of radionuclides
SG10202100683RA (en) 2016-08-31 2021-03-30 Oncotherapy Science Inc Monoclonal antibody against melk and utilization thereof
DK3509595T3 (da) 2016-09-06 2023-01-23 Univ California Formuleringer af hydroxypyridonat-actinid/lanthanid-dekorporeringsmidler
US11168148B2 (en) 2016-09-07 2021-11-09 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
MX2019002867A (es) 2016-09-19 2019-11-12 Celgene Corp Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
EP3515932B1 (en) 2016-09-19 2023-11-22 F. Hoffmann-La Roche AG Complement factor based affinity chromatography
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
PL3528838T3 (pl) 2016-09-23 2023-12-18 F. Hoffmann-La Roche Ag Zastosowania antagonistów IL-13 do leczenia atopowego zapalenia skóry
EP3520117B1 (en) 2016-09-29 2023-11-08 The Regents of The University of California Separation of metal ions by liquid-liquid extraction
CA3038670A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Chelating molecules
CN109843926B (zh) 2016-09-30 2023-01-20 豪夫迈·罗氏有限公司 针对cd3的双特异性抗体
JP2019529509A (ja) 2016-10-05 2019-10-17 アクセレロン ファーマ インコーポレーテッド 腎臓疾患を治療するための組成物および方法
EP3522933B1 (en) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Methods for preparing antibody drug conjugates
CA3038712A1 (en) 2016-10-06 2018-04-12 Genentech, Inc. Therapeutic and diagnostic methods for cancer
TWI762516B (zh) 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 針對ｆｚｄ１０之單株抗體及其用途
US10525083B2 (en) 2016-10-07 2020-01-07 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
EP3529618B1 (en) 2016-10-19 2020-12-02 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5 in a sample
JP7173965B2 (ja) 2016-10-19 2022-11-16 アレクシオン ファーマシューティカルズ， インコーポレイテッド 試料中の非結合Ｃ５ａの定量化方法
CN114773471A (zh) 2016-10-20 2022-07-22 天境生物科技(上海)有限公司 新的cd47单克隆抗体及其应用
EP3532496A1 (en) 2016-10-28 2019-09-04 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
EP3532091A2 (en) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
JP7784795B2 (ja) 2016-11-15 2025-12-12 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
KR20190077103A (ko) 2016-11-21 2019-07-02 오비아이 파머 인코퍼레이티드 접합된 생물학적 분자, 제약 조성물 및 방법
MY198942A (en) 2016-12-07 2023-10-03 Genentech Inc Anti-tau antibodies and methods of use
AU2017373884B2 (en) 2016-12-07 2024-11-14 Ac Immune Sa Anti-tau antibodies and methods of their use
JP7141407B2 (ja) 2016-12-13 2022-09-22 エフ．ホフマン－ラ ロシュ アーゲー 腫瘍試料における標的抗原の存在を決定する方法
MX2019007332A (es) 2016-12-19 2019-11-18 Tolero Pharmaceuticals Inc Péptidos indicadores y métodos para caracterizar sensibilidad.
JP7125400B2 (ja) 2016-12-19 2022-08-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 標的化４－１ｂｂ（ｃｄ１３７）アゴニストとの併用療法
BR112019007267A2 (pt) 2016-12-20 2019-07-09 Hoffmann La Roche anticorpo biespecífico anti-cd20/anti-cd3, produto farmacêutico, composição farmacêutica que compreende um anticorpo biespecífico anti-cd20/anti-cd3, uso de combinação de anticorpo biespecífico anti-cd20/anti-cd3 e um agonista de 4-1bb e método de tratamento ou retardamento da progressão de câncer em pacientes
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
CR20190309A (es) 2017-01-03 2019-08-21 Hoffmann La Roche Moleculas de unión de3 antígeno biespecíficas que comprenden el clon 20h4.9 anti-4-1bb
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
JP7069476B2 (ja) 2017-01-06 2022-05-18 博奥信生物技▲術▼（南京）有限公司 ＥｒｂＢ２抗体およびその使用
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
AR110873A1 (es) 2017-02-10 2019-05-08 Genentech Inc Anticuerpos contra triptasa, composiciones de estos y usos de estos
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
PL3589754T3 (pl) 2017-03-01 2023-10-09 F. Hoffmann-La Roche Ag Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
EP3589650A1 (en) 2017-03-02 2020-01-08 Novartis AG Engineered heterodimeric proteins
UA129242C2 (uk) 2017-03-22 2025-02-26 Дженентек, Інк. Оптимізована композиція антитіла для лікування захворювань очей
SG11201908547VA (en) 2017-03-22 2019-10-30 Genentech Inc Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
CR20190431A (es) 2017-03-27 2019-11-01 Hoffmann La Roche Formatos mejorados de receptor de unión a antígeno
WO2018177966A1 (en) 2017-03-27 2018-10-04 F. Hoffmann-La Roche Ag Improved antigen binding receptors
CN117205311A (zh) 2017-03-28 2023-12-12 基因泰克公司 治疗神经退行性疾病的方法
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
JP7205995B2 (ja) 2017-03-29 2023-01-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激性ｔｎｆ受容体に対する二重特異性抗原結合分子
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
CA3055132A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Antibodies binding to steap-1
EP3606947B1 (en) 2017-04-03 2022-12-21 F. Hoffmann-La Roche AG Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
EP4201953A1 (en) 2017-04-03 2023-06-28 F. Hoffmann-La Roche AG Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
CR20190427A (es) 2017-04-04 2019-11-01 Hoffmann La Roche Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap
ES3000582T3 (en) 2017-04-05 2025-02-28 Hoffmann La Roche Bispecific antibodies specifically binding to pd1 and lag3
CR20190434A (es) 2017-04-05 2019-11-01 Hoffmann La Roche Anticuerpos anti-lag3
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
CN108728444A (zh) 2017-04-18 2018-11-02 长春华普生物技术股份有限公司 免疫调节性多核苷酸及其应用
US12460208B2 (en) 2017-04-18 2025-11-04 Parr Biotechnology Co., Ltd. Immunomodulatory polynucleotides and uses thereof
CA3059615A1 (en) 2017-04-21 2018-10-25 Genentech, Inc. Use of klk5 antagonists for treatment of a disease
WO2018200742A1 (en) 2017-04-25 2018-11-01 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US11203638B2 (en) 2017-05-05 2021-12-21 Allakos Inc. Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis
EP3625251A1 (en) 2017-05-15 2020-03-25 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
US11359014B2 (en) 2017-05-16 2022-06-14 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
EP3630830A1 (en) 2017-05-23 2020-04-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
CN110785187B (zh) 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
WO2019006007A1 (en) 2017-06-27 2019-01-03 Novartis Ag POSOLOGICAL REGIMES FOR ANTI-TIM3 ANTIBODIES AND USES THEREOF
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
MX2019015293A (es) 2017-06-30 2020-02-17 Zymeworks Inc Fab quimericos estabilizados.
AU2018301393B2 (en) 2017-07-11 2025-02-27 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
US20200172617A1 (en) 2017-07-20 2020-06-04 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
CA3069469A1 (en) 2017-07-21 2019-01-24 Genentech, Inc. Therapeutic and diagnostic methods for cancer
AU2018308364C1 (en) 2017-07-26 2023-02-16 Forty Seven, LLC Anti-SIRP-alpha antibodies and related methods
JP7407699B2 (ja) 2017-07-28 2024-01-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗体製剤
UA129513C2 (uk) 2017-08-03 2025-05-21 ЕЛЕКТОР ЕлЕлСі Антитіло до trem2
KR102733407B1 (ko) 2017-08-03 2024-11-21 알렉터 엘엘씨 항-cd33 항체 및 이의 이용 방법
MX2020000903A (es) 2017-08-11 2020-07-22 Genentech Inc Anticuerpos anti-cd8 y usos de los mismos.
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
WO2019059411A1 (en) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
SG11201810270SA (en) 2017-09-29 2019-04-29 Chugai Pharmaceutical Co Ltd Multispecific antigen-binding molecules having blood coagulation factor viii (fviii) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ing
EA039662B1 (ru) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
US20200237766A1 (en) 2017-10-13 2020-07-30 Tolero Pharmaceuticals, Inc. Pkm2 activators in combination with reactive oxygen species for treatment of cancer
CN111246885B (zh) 2017-10-20 2024-06-11 豪夫迈·罗氏有限公司 从单特异性抗体生成多特异性抗体的方法
WO2019086362A1 (en) 2017-10-30 2019-05-09 F. Hoffmann-La Roche Ag Method for in vivo generation of multispecific antibodies from monospecific antibodies
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
AU2018358904A1 (en) 2017-11-01 2020-04-16 F. Hoffmann-La Roche Ag TriFab-contorsbody
CN111246884A (zh) 2017-11-01 2020-06-05 豪夫迈·罗氏有限公司 新颖的含有tnf家族配体三聚体的抗原结合分子
EP3704155A2 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Combination therapy with targeted ox40 agonists
CA3076027A1 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Bispecific 2+1 contorsbodies
WO2019086394A1 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag The compbody - a multivalent target binder
CN111213059B (zh) 2017-11-06 2024-01-09 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHOD OF USING
US20200277378A1 (en) 2017-11-16 2020-09-03 Novartis Ag Combination therapies
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019115659A1 (en) 2017-12-14 2019-06-20 F. Hoffmann-La Roche Ag Use of a cea cd3 bispecific antibody and a pd-1 axis binding antagonist in a dosage regime to treat cancer
MA51302A (fr) 2017-12-21 2021-03-31 Hoffmann La Roche Anticorps se liant à hla-a2/wt1
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
EP3729081B1 (en) 2017-12-21 2025-02-19 F. Hoffmann-La Roche AG Car-t cell assay for specificity test of novel antigen binding moieties
EP3729080B1 (en) 2017-12-21 2023-04-19 F. Hoffmann-La Roche AG Universal reporter cell assay for specificity test of novel antigen binding moieties
EP3728321A1 (en) 2017-12-22 2020-10-28 F. Hoffmann-La Roche AG Use of pilra binding agents for treatment of a disease
CN117050184A (zh) 2017-12-28 2023-11-14 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
EP3732203A4 (en) 2017-12-28 2021-12-15 Nanjing Legend Biotech Co., Ltd. ANTIBODIES AND THEIR VARIANTS DIRECTED AGAINST PD-L1
WO2019129677A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Anti-vegf antibodies and methods of use
CN111886246B (zh) 2017-12-29 2024-12-17 艾莱克特有限责任公司 抗tmem106b抗体及其使用方法
CN111818943B (zh) 2018-01-04 2024-09-03 伊科尼克治疗公司 抗组织因子抗体、抗体-药物缀合物及相关方法
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
SG11202004233UA (en) 2018-01-15 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against pd-1
CA3088649A1 (en) 2018-01-16 2019-07-25 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
JP2021511782A (ja) 2018-01-31 2021-05-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 安定化された免疫グロブリンドメイン
WO2019152660A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
CN111655730A (zh) 2018-01-31 2020-09-11 豪夫迈·罗氏有限公司 包含与lag3结合的抗原结合位点的双特异性抗体
EP3746476A1 (en) 2018-01-31 2020-12-09 Alector LLC Anti-ms4a4a antibodies and methods of use thereof
CN111712261B (zh) 2018-02-08 2024-08-09 豪夫迈·罗氏有限公司 双特异性抗原结合分子和使用方法
CA3090538A1 (en) 2018-02-09 2019-08-15 Acceleron Pharma, Inc. Methods for treating heterotopic ossification
AU2019218128A1 (en) 2018-02-09 2020-09-17 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
US20200399376A1 (en) 2018-02-26 2020-12-24 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2019166453A1 (en) 2018-03-01 2019-09-06 F. Hoffmann-La Roche Ag Specificity assay for novel target antigen binding moieties
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
CN119074915A (zh) 2018-03-13 2024-12-06 豪夫迈·罗氏有限公司 4-1bb激动剂与抗cd20抗体的治疗剂组合
RU2020128013A (ru) 2018-03-14 2022-04-15 Бейцзин Сюаньи Фармасайенсиз Ко., Лтд. Антитела против клаудина 18.2
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
WO2019179420A1 (en) 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-tim-3 antibodies
KR20200133376A (ko) 2018-03-21 2020-11-27 알렉소 온콜로지 인크. 신호-조절 단백질 알파에 대한 항체 및 사용 방법
CN111936625B (zh) 2018-03-29 2025-02-07 豪夫迈·罗氏有限公司 调节哺乳动物细胞中的生乳活性
EP3778639A4 (en) 2018-04-02 2021-06-09 Mab-Venture Biopharm Co., Ltd. LYMPHOCYTE ANTIGEN-3 (LAG-3) BINDING ANTIBODY AND ITS USES
WO2019192972A1 (en) 2018-04-04 2019-10-10 F. Hoffmann-La Roche Ag Diagnostic assays to detect tumor antigens in cancer patients
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
EP3775902B1 (en) 2018-04-04 2023-02-22 F. Hoffmann-La Roche AG Diagnostic assays to detect tumor antigens in cancer patients
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CR20200459A (es) 2018-04-13 2020-11-11 Hoffmann La Roche Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
JP7402541B2 (ja) 2018-05-03 2023-12-21 ユニバーシティ オブ ロチェスター 抗インフルエンザノイラミニダーゼモノクローナル抗体およびその使用
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
KR20210021467A (ko) 2018-05-14 2021-02-26 웨어울프 세라퓨틱스, 인크. 활성화가능한 인터루킨-2 폴리펩타이드 및 이의 사용 방법
AU2019269066B2 (en) 2018-05-18 2022-10-06 F. Hoffmann-La Roche Ag Targeted intracellular delivery of large nucleic acids
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
WO2019226617A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
MA52753A (fr) 2018-05-25 2021-04-21 Alector Llc Anticorps anti-sirpa et leurs procédés d'utilisation
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
US20210238308A1 (en) 2018-06-04 2021-08-05 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule showing changed half-life in cytoplasm
EA202092595A1 (ru) 2018-06-08 2021-04-12 Алектор Ллс Антитела к siglec-7 и способы их применения
WO2019241426A1 (en) 2018-06-13 2019-12-19 Novartis Ag Bcma chimeric antigen receptors and uses thereof
KR20210021486A (ko) 2018-06-18 2021-02-26 안위타 바이오사이언시스, 인코포레이티드 사이토카인 융합 단백질 및 이의 용도
PE20210418A1 (es) 2018-06-19 2021-03-08 Atarga Llc Moleculas de anticuerpo de componente de complemento 5 y sus usos
MX2020014091A (es) 2018-06-23 2021-05-27 Genentech Inc Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un agente de platino y un inhibidor de la topoisomerasa ii.
TWI853822B (zh) 2018-06-27 2024-09-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
US20210355199A1 (en) 2018-06-28 2021-11-18 University Of Virginia Patent Foundation Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling
KR20210025614A (ko) 2018-06-29 2021-03-09 알렉터 엘엘씨 항-sirp-베타1 항체 및 그의 사용 방법
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
TW202035447A (zh) 2018-07-04 2020-10-01 瑞士商赫孚孟拉羅股份公司 新穎雙特異性促效性4-1bb抗原結合分子
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
ES2940311T3 (es) 2018-07-13 2023-05-05 Alector Llc Anticuerpos anti-sortilina y métodos de uso de los mismos
KR20210034622A (ko) 2018-07-18 2021-03-30 제넨테크, 인크. Pd-1 축 결합 길항제, 항 대사제, 및 백금 제제를 이용한 폐암 치료 방법
SG11202100373VA (en) 2018-07-20 2021-02-25 Surface Oncology Inc Anti-cd112r compositions and methods
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
WO2020023910A1 (en) 2018-07-26 2020-01-30 Tolero Pharmaceuticals, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
JP7535495B2 (ja) 2018-07-27 2024-08-16 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－５抗体及びその使用方法
JP7504027B2 (ja) 2018-08-03 2024-06-21 中外製薬株式会社 互いに連結された２つの抗原結合ドメインを含む抗原結合分子
AR115925A1 (es) 2018-08-08 2021-03-10 Genentech Inc Uso de derivados de triptófano y l-metionina para formulación de proteínas
EP3835321A4 (en) 2018-08-10 2022-11-02 Chugai Seiyaku Kabushiki Kaisha ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
US11548938B2 (en) 2018-08-21 2023-01-10 Quidel Corporation DbpA antibodies and uses thereof
TW202023625A (zh) 2018-08-23 2020-07-01 美商西雅圖遺傳學公司 抗tigit抗體
PE20211096A1 (es) 2018-08-31 2021-06-14 Alector Llc Anticuerpos anti-cd33 y metodos para usarlos
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP3850013A4 (en) 2018-09-10 2022-10-05 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AGAINST CLL1 AND USES THEREOF
AR114732A1 (es) 2018-09-18 2020-10-07 Hoffmann La Roche Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco
JP2022501332A (ja) 2018-09-19 2022-01-06 ジェネンテック， インコーポレイテッド 膀胱がんの治療方法および診断方法
MX2021003213A (es) 2018-09-21 2021-05-12 Genentech Inc Metodos de diagnostico para cancer de mama triple negativo.
PE20211491A1 (es) 2018-09-27 2021-08-11 Celgene Corp PROTEINAS DE FIJACION A SIRPa Y METODOS DE USO DE ESTAS
EP3856764A4 (en) 2018-09-27 2022-11-02 Xilio Development, Inc. MASKED CYTOKINE POLYPEPTIDES
TW202019958A (zh) 2018-09-28 2020-06-01 日商協和麒麟股份有限公司 Il-36抗體及其用途
CN112654641A (zh) 2018-10-01 2021-04-13 豪夫迈·罗氏有限公司 具有与cd40的三价结合的双特异性抗原结合分子
CR20210154A (es) 2018-10-01 2021-04-21 Hoffmann La Roche Moléculas de unión a antígeno bioespecíficas que comprenden el clon 212 anti-fap
US20200109200A1 (en) 2018-10-09 2020-04-09 Genentech, Inc. Methods and systems for determining synapse formation
CN113196061A (zh) 2018-10-18 2021-07-30 豪夫迈·罗氏有限公司 肉瘤样肾癌的诊断和治疗方法
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
KR20210090645A (ko) 2018-11-05 2021-07-20 제넨테크, 인크. 원핵 숙주 세포에서 2개의 사슬 단백질을 생산하는 방법
KR20210107628A (ko) 2018-11-13 2021-09-01 콤파스 테라퓨틱스 엘엘씨 체크포인트 분자에 대한 다중특이적 결합 작제물 및 이의 용도
US20220364171A1 (en) 2018-11-23 2022-11-17 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease
AU2019391097B2 (en) 2018-12-04 2025-07-03 Sumitomo Pharma America, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020117257A1 (en) 2018-12-06 2020-06-11 Genentech, Inc. Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
KR20210106484A (ko) 2018-12-20 2021-08-30 노파르티스 아게 Hdm2-p53 상호작용 억제제와 bcl2 억제제의 조합 및 암 치료를 위한 이의 용도
US12234292B2 (en) 2018-12-20 2025-02-25 Kyowa Kirin Co., Ltd. FN14 antibodies and uses thereof
CN113271945A (zh) 2018-12-20 2021-08-17 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
UA128001C2 (uk) 2018-12-21 2024-03-06 Ф. Хоффманн-Ля Рош Аг Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули
MA54514A (fr) 2018-12-21 2022-03-30 Hoffmann La Roche Anticorps se liant à cd3
KR20210107721A (ko) 2018-12-21 2021-09-01 23앤드미 인코포레이티드 항-il-36 항체 및 이의 사용 방법
EP3898984A1 (en) 2018-12-21 2021-10-27 Genentech, Inc. Methods of producing polypeptides using a cell line resistant to apoptosis
TW202030204A (zh) 2018-12-21 2020-08-16 瑞士商赫孚孟拉羅股份公司 靶向腫瘤之超促效cd28抗原結合分子
BR112021012631A2 (pt) 2018-12-26 2021-12-14 Xilio Dev Inc Anticorpos anti-ctla4 e métodos de uso dos mesmos
CN113272327A (zh) 2018-12-30 2021-08-17 豪夫迈·罗氏有限公司 抗兔cd19抗体及其使用方法
BR112021013337A2 (pt) 2019-01-07 2021-11-09 Bactolife Aps Proteínas de ligação a patógenos
CA3124837A1 (en) 2019-01-14 2020-07-23 Genentech, Inc. Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
US20220089770A1 (en) 2019-01-24 2022-03-24 Chugai Seiyaku Kabushiki Kaisha Novel cancer antigens and antibodies of said antigens
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
US11471456B2 (en) 2019-02-12 2022-10-18 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
WO2020169698A1 (en) 2019-02-21 2020-08-27 F. Hoffmann-La Roche Ag Sensitization of cancer cells to tnf by bet inhibition
EP3927371A1 (en) 2019-02-22 2021-12-29 Novartis AG Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
WO2020176794A1 (en) 2019-02-27 2020-09-03 Angiex, Inc. Antibody-drug conjugates comprising anti-tm4sf1 antibodies and methods of using the same
BR112021016923A2 (pt) 2019-02-27 2021-11-03 Genentech Inc Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
AU2020238811A1 (en) 2019-03-08 2021-07-22 Genentech, Inc. Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
EP3938784A1 (en) 2019-03-13 2022-01-19 Merck Patent GmbH Process for the preparation of lipidated proteinaceous structures
MA55296A (fr) 2019-03-14 2022-03-23 Hoffmann La Roche Traitement du cancer avec des anticorps bispécifiques de her2xcd3 en combinaison avec un mab anti-her2
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
CN113747895A (zh) 2019-03-22 2021-12-03 大日本住友制药肿瘤公司 包含pkm2调节剂的组合物和用其治疗的方法
CN113950355A (zh) 2019-03-29 2022-01-18 阿塔盖有限责任公司 Fgf23的抗体分子和其用途
JP2022527565A (ja) 2019-04-12 2022-06-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ＣＥＡ ＣＤ３二重特異性抗体及びＷｎｔシグナル伝達阻害剤を使用するがんの治療
CN113677403B (zh) 2019-04-12 2024-12-27 豪夫迈·罗氏有限公司 包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
BR112021019571A2 (pt) 2019-04-19 2021-12-07 Chugai Pharmaceutical Co Ltd Receptor quimérico que reconhece o sítio de modificação do anticorpo
JP7593939B2 (ja) 2019-04-19 2024-12-03 ジェネンテック， インコーポレイテッド 抗ｍｅｒｔｋ抗体及びその使用方法
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
EP3962947A2 (en) 2019-05-03 2022-03-09 F. Hoffmann-La Roche AG Methods of treating cancer with an anti-pd-l1 antibody
EP3965891A1 (en) 2019-05-10 2022-03-16 Takeda Pharmaceutical Company Limited Antibody drug conjugates
JP7754723B2 (ja) 2019-05-14 2025-10-15 ウェアウルフ セラピューティクス， インコーポレイテッド 分離部分及びその使用方法
JP7550794B2 (ja) 2019-05-14 2024-09-13 ジェネンテック， インコーポレイテッド 濾胞性リンパ腫を処置するための抗ｃｄ７９ｂ免疫複合体の使用方法
WO2020232262A1 (en) 2019-05-16 2020-11-19 Procisedx Inc. Assay detection methods for vcam-1 and calprotectin
WO2020232295A1 (en) 2019-05-16 2020-11-19 Procisedx Inc. An assay method for the detection of vcam-1 and alpha-2-macroglobulin in blood
JP2022534227A (ja) 2019-05-23 2022-07-28 プロサイセデクス インコーポレイティド ヒト血清アルブミン、ビタミンｄ、ｃ反応性タンパク質、及び抗トランスグルタミナーゼ自己抗体の検出のためのアッセイ方法
TWI870412B (zh) 2019-06-05 2025-01-21 美商建南德克公司 過載層析管柱之再生方法
EP3980779A1 (en) 2019-06-06 2022-04-13 ProciseDx Inc. Detection of hemoglobin a1c (hba1c) in blood
CA3140023A1 (en) 2019-06-11 2020-12-17 Alector Llc Anti-sortilin antibodies for use in therapy
EP3990922A1 (en) 2019-06-25 2022-05-04 ProciseDx Inc. Detection of anti-tnf alpha drug biologics and anti-drug antibodies
EP3990477A1 (en) 2019-06-26 2022-05-04 F. Hoffmann-La Roche AG Fusion of an antibody binding cea and 4-1bbl
EP3990492A1 (en) 2019-06-27 2022-05-04 F. Hoffmann-La Roche AG Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
AU2020304649B2 (en) 2019-06-28 2025-09-04 Genentech, Inc. Composition and methods for stabilizing liquid protein formulations
EP3994169A1 (en) 2019-07-02 2022-05-11 F. Hoffmann-La Roche AG Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
EP3998083A4 (en) 2019-07-12 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Anti-mutation type fgfr3 antibody and use therefor
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
CN114423787B (zh) 2019-07-19 2025-01-24 昂科里斯庞斯公司 免疫调节性抗体及其使用方法
EP4004045A1 (en) 2019-07-31 2022-06-01 F. Hoffmann-La Roche AG Antibodies binding to gprc5d
CR20220078A (es) 2019-07-31 2022-06-24 Alector Llc Anticuerpos anti-ms4a4a y métodos de uso de los mismos
CN114174342B (zh) 2019-07-31 2024-08-16 豪夫迈·罗氏有限公司 与gprc5d结合的抗体
CA3146616A1 (en) 2019-09-12 2021-03-18 Matthew Dominic CASCINO Compositions and methods of treating lupus nephritis
MX2022003212A (es) 2019-09-18 2022-04-25 Genentech Inc Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso.
CN114423454A (zh) 2019-09-20 2022-04-29 豪夫迈·罗氏有限公司 抗类胰蛋白酶抗体的给药
US20220281997A1 (en) 2019-09-27 2022-09-08 Nanjing GenScript Biotech Co., Ltd. Anti-VHH Domain Antibodies and Use Thereof
WO2021062085A1 (en) 2019-09-27 2021-04-01 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021076196A1 (en) 2019-10-18 2021-04-22 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
JP2022553293A (ja) 2019-10-21 2022-12-22 ノバルティス アーゲー ベネトクラックスおよびｔｉｍ－３阻害剤を用いた併用療法
BR112022007179A2 (pt) 2019-10-21 2022-08-23 Novartis Ag Inibidores de tim-3 e usos dos mesmos
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
BR112022008652A2 (pt) 2019-11-05 2022-07-19 Hoffmann La Roche Anticorpos biespecíficos hla-a2/wt1 x cd3, uso de um anticorpo biespecífico, método para tratar câncer em um indivíduo, kit e invenção
KR20220092580A (ko) 2019-11-06 2022-07-01 제넨테크, 인크. 혈액암의 치료를 위한 진단과 치료 방법
WO2021096888A1 (en) 2019-11-12 2021-05-20 Foundation Medicine, Inc. Methods of detecting a fusion gene encoding a neoantigen
KR20220101147A (ko) 2019-11-14 2022-07-19 웨어울프 세라퓨틱스, 인크. 활성화가능한 사이토카인 폴리펩티드 및 이의 사용 방법
WO2021108661A2 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
IL293386A (en) 2019-12-05 2022-07-01 Alector Llc Methods of use of anti-trem2 antibodies
US12076400B2 (en) 2019-12-06 2024-09-03 Zymeworks Bc Inc. Methods of using a bispecific antigen-binding construct targeting HER2 in combination with CDK4/6 inhibitors for the treatment of breast cancer
CN115066437A (zh) 2019-12-12 2022-09-16 艾利妥 使用抗cd33抗体的方法
AR120741A1 (es) 2019-12-13 2022-03-16 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso
CR20220329A (es) 2019-12-13 2022-11-23 Alector Llc Anticuerpos anti–mertk y metodos de uso de los mismos
CN114828965B (zh) 2019-12-18 2025-09-05 豪夫迈·罗氏有限公司 与hla-a2/mage-a4结合的抗体
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
WO2021121215A1 (en) 2019-12-20 2021-06-24 Shandong Boan Biotechnology Co., Ltd. Optimized anti-cd3 arm in the generation of t-cell bispecific antibodies for immunotherapy
MX2022007746A (es) 2019-12-23 2022-10-07 Genentech Inc Anticuerpos especificos de apolipoproteina l1 y metodos de uso.
MY202559A (en) 2019-12-27 2024-05-08 Chugai Pharmaceutical Co Ltd Anti-ctla-4 antibody and use thereof
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
IL292780A (en) 2020-01-09 2022-07-01 Hoffmann La Roche A new 4-1bbl trimer containing antigen-binding molecules
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
KR20220128389A (ko) 2020-01-17 2022-09-20 노파르티스 아게 골수이형성 증후군 또는 만성 골수단핵구성 백혈병을 치료하는데 사용하기 위한 tim-3 억제제 및 저메틸화제를 포함하는 조합물
WO2021146636A1 (en) 2020-01-17 2021-07-22 Becton, Dickinson And Company Methods and compositions for single cell secretomics
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
CA3164559A1 (en) 2020-01-31 2021-08-05 Lars Mueller Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
US20230078601A1 (en) 2020-01-31 2023-03-16 The Cleveland Clinic Foundation Anti-mullerian hormone receptor 2 antibodies and methods of use
EP4105237A4 (en) 2020-02-10 2024-03-27 Shanghai Escugen Biotechnology Co., Ltd. ANTI-CLDN18.2 ANTIBODIES AND ITS USE
JP7522482B2 (ja) 2020-02-10 2024-07-25 上海詩健生物科技有限公司 クローディン１８．２の抗体及びその使用
TWI895351B (zh) 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
EP4110814A1 (en) 2020-02-24 2023-01-04 Alector LLC Methods of use of anti-trem2 antibodies
CN115397460A (zh) 2020-02-27 2022-11-25 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
EP4118120A4 (en) 2020-03-12 2024-04-17 Immune-ONC Therapeutics, Inc. NOVEL ANTI-LILRB4 ANTIBODIES AND DERIVATIVE PRODUCTS
EP4118114A1 (en) 2020-03-13 2023-01-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
KR20250074688A (ko) 2020-03-19 2025-05-27 제넨테크, 인크. 동종형 선택적 항-tgf-베타 항체 및 이용 방법
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
PH12022552267A1 (en) 2020-03-24 2024-02-19 Genentech Inc Tie2-binding agents and methods of use
CA3169908A1 (en) 2020-03-26 2021-09-30 Genentech, Inc. Modified mammalian cells having reduced host cell proteins
JP2023519962A (ja) 2020-03-31 2023-05-15 アレクトル エルエルシー 抗ｍｅｒｔｋ抗体及びその使用方法
EP4574971A3 (en) 2020-03-31 2026-01-14 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Proteomic screening for lysosomal storage diseases
IL296802A (en) 2020-03-31 2022-11-01 Chugai Pharmaceutical Co Ltd A method for the production of multispecific antigen binding molecules
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
EP4126934A1 (en) 2020-04-01 2023-02-08 University of Rochester Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
EP4126939A4 (en) 2020-04-02 2024-08-21 Seattle Children's Hospital d/b/a Seattle Children's Research Institute ANTIBODIES THAT BIND SPECIFICALLY TO PEPTIDES ASSOCIATED WITH PRIMARY IMMUNODEFICIENCIES: WISKOTT-ALDRICH SYNDROME AND X-LINKED AGAMMAGLOBULINEMIA
AU2021247286A1 (en) 2020-04-03 2022-10-20 Alector Llc Methods of use of anti-TREM2 antibodies
WO2021202959A1 (en) 2020-04-03 2021-10-07 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2021205032A1 (en) 2020-04-09 2021-10-14 Technische Universität München Targeted delivery of an inhibitor of mir-21 to macrophages for the treatment of pulmonary fibrosis
CN116249712A (zh) 2020-04-15 2023-06-09 沃雅戈治疗公司 Tau结合化合物
AU2021256936A1 (en) 2020-04-15 2022-07-21 F. Hoffmann-La Roche Ag Immunoconjugates
IL297541A (en) 2020-04-24 2022-12-01 Genentech Inc Methods for using anti-cd79b immunoconjugates
PE20230078A1 (es) 2020-04-24 2023-01-11 Hoffmann La Roche Modulacion de enzimas y vias con compuestos de sulfhidrilo y sus derivados
WO2021222181A2 (en) 2020-04-27 2021-11-04 The Regents Of The University Of California Isoform-independent antibodies to lipoprotein(a)
SG11202112792WA (en) 2020-04-28 2021-12-30 Univ Rockefeller Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
CN115885050A (zh) 2020-04-28 2023-03-31 基因泰克公司 用于非小细胞肺癌免疫疗法的方法和组合物
WO2021222533A1 (en) 2020-04-30 2021-11-04 Procisedx Inc. Methods of detecting antibodies to sars-cov-2
KR20230087414A (ko) 2020-05-03 2023-06-16 레베나 (쑤저우) 바이오파마 컴퍼니 리미티드 항-Trop-2 항체를 포함하는 항체-약물 접합체 (ADCS), 상기 ADCS를 포함하는 조성물, 및 이의 제조 및 사용 방법
EP4149964A2 (en) 2020-05-15 2023-03-22 Apogenix AG Multi-specific immune modulators
CN116323665A (zh) 2020-05-29 2023-06-23 23和我公司 抗cd200r1抗体及其使用方法
AU2021288916A1 (en) 2020-06-08 2022-11-24 F.Hoffmann-La Roche Ag Anti-HBV antibodies and methods of use
KR20230023727A (ko) 2020-06-11 2023-02-17 제넨테크, 인크. 나노지단백질-폴리펩티드 접합체 및 조성물, 시스템, 및 이의 사용 방법
WO2021252977A1 (en) 2020-06-12 2021-12-16 Genentech, Inc. Methods and compositions for cancer immunotherapy
AU2021293038A1 (en) 2020-06-16 2023-02-02 F. Hoffmann-La Roche Ag Methods and compositions for treating triple-negative breast cancer
CA3181672A1 (en) 2020-06-18 2021-12-23 Shi Li Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
EP4168446A1 (en) 2020-06-19 2023-04-26 F. Hoffmann-La Roche AG Antibodies binding to cd3 and folr1
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
EP4168444A1 (en) 2020-06-19 2023-04-26 F. Hoffmann-La Roche AG Protease-activated t cell bispecific antibodies
PE20230835A1 (es) 2020-06-19 2023-05-19 Hoffmann La Roche Anticuerpos que se unen a cd3
TW202519548A (zh) 2020-06-19 2025-05-16 瑞士商赫孚孟拉羅股份公司 與 cd3 及 cd19 結合之抗體
CN116234824A (zh) 2020-06-22 2023-06-06 阿尔米雷尔有限公司 抗il-36抗体及其使用方法
US12049515B2 (en) 2020-06-23 2024-07-30 Hoffmann-La Roche Inc. Agonistic CD28 antigen binding molecules targeting Her2
JP7644151B2 (ja) 2020-06-23 2025-03-11 カドモン コーポレイション，リミティド ライアビリティ カンパニー 抗ｐｄ－１抗体および融合タンパク質
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
JP2023533217A (ja) 2020-06-24 2023-08-02 ジェネンテック， インコーポレイテッド アポトーシス耐性細胞株
WO2021260064A1 (en) 2020-06-25 2021-12-30 F. Hoffmann-La Roche Ag Anti-cd3/anti-cd28 bispecific antigen binding molecules
CN115698072B (zh) 2020-07-01 2023-07-04 山东博安生物技术股份有限公司 抗gpc3抗体，抗gpc3嵌合抗原受体和gpc3/cd3双特异性抗体
WO2022008688A1 (en) 2020-07-10 2022-01-13 F. Hoffmann-La Roche Ag Antibodies which bind to cancer cells and target radionuclides to said cells
WO2022015726A1 (en) 2020-07-13 2022-01-20 Genentech, Inc. Cell-based methods for predicting polypeptide immunogenicity
IL299586A (en) 2020-07-16 2023-03-01 Novartis Ag Anti-betacellulin antibodies, their fragments, and multispecific binding molecules
CA3185122A1 (en) 2020-07-17 2022-01-20 Cecilia Pui Chi Chiu Anti-notch2 antibodies and methods of use
AR123019A1 (es) 2020-07-21 2022-10-26 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo de brm y métodos de estos
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4192942A1 (en) 2020-08-07 2023-06-14 Genentech, Inc. T cell-based methods for predicting polypeptide immunogenicity
TW202227625A (zh) 2020-08-28 2022-07-16 美商建南德克公司 宿主細胞蛋白質之ＣＲＩＳＰＲ／Ｃａｓ９多重剔除
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4211165A1 (en) 2020-09-14 2023-07-19 Ichnos Sciences SA Antibodies that bind to il1rap and uses thereof
CA3193478A1 (en) 2020-09-24 2022-03-31 F. Hoffmann-La Roche Ag Prevention or mitigation of t-cell bispecific antibody-related adverse effects
MX2023003756A (es) 2020-10-05 2023-04-24 Genentech Inc Dosis para el tratamiento con anticuerpos biespecificos anti-fcrh5/anti-cd3.
CA3190782A1 (en) 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Combination therapy of pd-1 axis binding antagonists and lrrk2 inhibitors
AR123855A1 (es) 2020-10-20 2023-01-18 Genentech Inc Anticuerpos anti-mertk conjugados con peg y métodos de uso
US20240025992A1 (en) 2020-10-22 2024-01-25 Janssen Biotech, Inc. Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
EP4237450A1 (en) 2020-10-30 2023-09-06 F. Hoffmann-La Roche AG Treatment of cancer using a cea cd3 bispecific antibody and a tgfbeta signaling inhibitor
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
WO2022098870A1 (en) 2020-11-04 2022-05-12 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
CA3196076A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
JP7762198B2 (ja) 2020-11-04 2025-10-29 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体及び抗ｃｄ７９ｂ抗体薬物コンジュゲートによる処置のための投与
US20240002509A1 (en) 2020-11-06 2024-01-04 Novartis Ag ANTIBODY Fc VARIANTS
IL302402A (en) 2020-11-08 2023-06-01 Seagen Inc Combination therapy
MX2023005381A (es) 2020-11-09 2023-05-23 Takeda Pharmaceuticals Co Conjugados de anticuerpo y farmaco.
KR20230107235A (ko) 2020-11-10 2023-07-14 에프. 호프만-라 로슈 아게 T 세포 관여제 관련 부정적인 효과의 예방 또는 완화
MX2023005609A (es) 2020-11-13 2023-05-29 Novartis Ag Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car).
CA3200954A1 (en) 2020-11-16 2022-05-19 F. Hoffmann-La Roche Ag Fab high mannose glycoforms
CN117916261A (zh) 2020-11-16 2024-04-19 豪夫迈·罗氏有限公司 与靶向fap的cd40激动剂的组合疗法
TW202235431A (zh) 2020-11-25 2022-09-16 美商艾希利歐發展股份有限公司 腫瘤特異性可裂解連接子
CA3198003A1 (en) 2020-12-02 2022-06-09 Jiin-Tarng WANG Anti-garp/tgf? antibodies and methods of use
WO2022120352A1 (en) 2020-12-02 2022-06-09 Alector Llc Methods of use of anti-sortilin antibodies
MX2023006480A (es) 2020-12-04 2023-06-19 Hoffmann La Roche Polipeptidos de interleucina-2 mutante dependientes del ph.
BR112023008265A2 (pt) 2020-12-07 2024-02-06 UCB Biopharma SRL Anticorpos contra interleucina-22
US20240067758A1 (en) 2020-12-07 2024-02-29 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
PE20240819A1 (es) 2020-12-17 2024-04-18 Hoffmann La Roche Anticuerpos anti-hla-g y uso de estos
JP2024502832A (ja) 2020-12-31 2024-01-23 アラマー バイオサイエンシーズ， インコーポレイテッド 高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
EP4274658A1 (en) 2021-01-06 2023-11-15 F. Hoffmann-La Roche AG Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
AU2022207615A1 (en) 2021-01-12 2023-07-13 F. Hoffmann-La Roche Ag Split antibodies which bind to cancer cells and target radionuclides to said cells
CA3204291A1 (en) 2021-01-13 2022-07-21 F. Hoffmann-La Roche Ag Combination therapy
US12060411B2 (en) 2021-01-15 2024-08-13 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
KR20230147624A (ko) 2021-01-20 2023-10-23 온코리스폰스 인크. 면역조절 항체 및 이의 용도
CN116917326A (zh) 2021-01-22 2023-10-20 博泰康医药公司 抗her-2/trop-2构建体及其用途
US20240141060A1 (en) 2021-01-29 2024-05-02 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
US20220306743A1 (en) 2021-03-01 2022-09-29 Xilio Development, Inc. Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
TW202246324A (zh) 2021-03-01 2022-12-01 美商艾希利歐發展股份有限公司 用於治療癌症的經掩蔽之ｃｔｌａ４及ｐｄ１／ｐｄｌ１抗體之組合
CA3210069A1 (en) 2021-03-03 2022-09-09 Tong Zhu Antibody-drug conjugates comprising an anti-bcma antibody
WO2022192647A1 (en) 2021-03-12 2022-09-15 Genentech, Inc. Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
EP4454652A3 (en) 2021-03-15 2025-05-21 F. Hoffmann-La Roche AG Compositions and methods for treating lupus nephritis
CN116981696A (zh) 2021-03-18 2023-10-31 艾莱克特有限责任公司 抗tmem106b抗体及其使用方法
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
EP4314063A1 (en) 2021-03-23 2024-02-07 Alector LLC Anti-tmem106b antibodies for treating and preventing coronavirus infections
GB202104104D0 (en) 2021-03-24 2021-05-05 Liliumx Ltd Platform and method
JP2024513172A (ja) 2021-03-26 2024-03-22 ヤンセン バイオテツク，インコーポレーテツド 対らせん状細線維タウに対するヒト化抗体及びその使用
JP2024512709A (ja) 2021-03-30 2024-03-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化ポリペプチド
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AU2022254727A1 (en) 2021-04-09 2023-10-12 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
TW202305122A (zh) 2021-04-19 2023-02-01 美商建南德克公司 經修飾之哺乳動物細胞
EP4326271A1 (en) 2021-04-23 2024-02-28 F. Hoffmann-La Roche AG Prevention or mitigation of nk cell engaging agent-related adverse effects
AU2021443863A1 (en) 2021-04-30 2023-10-26 F. Hoffmann-La Roche Ag Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
JP2024517535A (ja) 2021-04-30 2024-04-23 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体と抗ｃｄ７９ｂ抗体薬物コンジュゲートを用いた併用治療の投与
WO2022233764A1 (en) 2021-05-03 2022-11-10 UCB Biopharma SRL Antibodies
WO2022235867A2 (en) 2021-05-06 2022-11-10 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
EP4337266A1 (en) 2021-05-12 2024-03-20 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
EP4337317A1 (en) 2021-05-14 2024-03-20 Genentech, Inc. Agonists of trem2
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
EP4341385A1 (en) 2021-05-21 2024-03-27 Genentech, Inc. Modified cells for the production of a recombinant product of interest
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
WO2022255440A1 (en) 2021-06-04 2022-12-08 Chugai Seiyaku Kabushiki Kaisha Anti-ddr2 antibodies and uses thereof
AU2022289684A1 (en) 2021-06-09 2023-10-05 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
EP4355783A1 (en) 2021-06-16 2024-04-24 Alector LLC Monovalent anti-mertk antibodies and methods of use thereof
CN117642426A (zh) 2021-06-16 2024-03-01 艾莱克特有限责任公司 双特异性抗MerTK和抗PDL1抗体及其使用方法
EP4355773A4 (en) 2021-06-18 2025-08-13 Therini Bio Inc ANTIBODIES THAT BIND TO THE GAMMA C DOMAIN OF HUMAN FIBRIN OR FIBRINOGEN AND METHODS OF USE
WO2022270612A1 (ja) 2021-06-25 2022-12-29 中外製薬株式会社 抗ｃｔｌａ－４抗体の使用
MX2023013897A (es) 2021-06-25 2023-12-11 Chugai Pharmaceutical Co Ltd Anticuerpo anti-antigeno 4 del linfocito t citotoxico (anti-ctla-4).
CA3223534A1 (en) 2021-07-02 2023-01-05 Genentech, Inc. Methods and compositions for treating cancer
MX2024000611A (es) 2021-07-14 2024-02-02 Genentech Inc Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso.
EP4373859A1 (en) 2021-07-22 2024-05-29 F. Hoffmann-La Roche AG Heterodimeric fc domain antibodies
EP4373576A1 (en) 2021-07-22 2024-05-29 Genentech, Inc. Brain targeting compositions and methods of use thereof
WO2023010095A1 (en) 2021-07-28 2023-02-02 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
JP2024528217A (ja) 2021-08-03 2024-07-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗体および使用方法
EP4384553A1 (en) 2021-08-13 2024-06-19 Genentech, Inc. Dosing for anti-tryptase antibodies
CA3229448A1 (en) 2021-08-23 2023-03-02 Immunitas Therapeutics, Inc. Anti-cd161 antibodies and uses thereof
KR20240049296A (ko) 2021-08-27 2024-04-16 제넨테크, 인크. 타우 병증을 치료하는 방법
TW202325727A (zh) 2021-08-30 2023-07-01 美商建南德克公司 抗聚泛素多特異性抗體
EP4405396A2 (en) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023056240A2 (en) 2021-09-28 2023-04-06 Frontaim Biomedicines, Inc. Multiple formats of molecular complexes
WO2023053282A1 (ja) 2021-09-29 2023-04-06 中外製薬株式会社 がんの治療に用いるための細胞傷害誘導治療剤
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
US20240404622A1 (en) 2021-10-08 2024-12-05 Chugai Seiyaku Kabushiki Kaisha Method for preparing prefilled syringe formulation
WO2023062048A1 (en) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag Alternative pd1-il7v immunoconjugates for the treatment of cancer
PE20241627A1 (es) 2021-10-14 2024-08-07 Hoffmann La Roche Nuevos inmunoconjugados de interleucina-7
WO2023069919A1 (en) 2021-10-19 2023-04-27 Alector Llc Anti-cd300lb antibodies and methods of use thereof
EP4426735A1 (en) 2021-11-01 2024-09-11 F. Hoffmann-La Roche AG Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and a 4-1bb (cd137) agonist
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
EP4430072A1 (en) 2021-11-10 2024-09-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators
WO2023088889A1 (en) 2021-11-16 2023-05-25 Apogenix Ag CD137 ligands
WO2023091887A1 (en) 2021-11-16 2023-05-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
JP2024543942A (ja) 2021-12-01 2024-11-26 カドモン コーポレイション，リミティド ライアビリティ カンパニー Ｂ７－ｈ４抗体及び抗ｂ７－ｈ４抗体／ｉｌ－１５融合タンパク質
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
EP4448560A1 (en) 2021-12-14 2024-10-23 F. Hoffmann-La Roche AG Treatment of cancer using a hla-a2/mage-a4 x cd3 bispecific antibody and a 4-1bb (cd137) agonist
WO2023114544A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Antibodies and uses thereof
WO2023114543A2 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
JP2025501522A (ja) 2021-12-17 2025-01-22 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｏｘ４０抗体及び使用方法
KR20240116755A (ko) 2021-12-17 2024-07-30 상하이 헨리우스 바이오테크, 인크. 항-ox40 항체, 다중 특이적 항체 및 이의 사용 방법
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
UY40097A (es) 2022-01-07 2023-07-14 Johnson & Johnson Entpr Innovation Inc Materiales y métodos de proteínas de unión a il-1b
US20230322958A1 (en) 2022-01-19 2023-10-12 Genentech, Inc. Anti-Notch2 Antibodies and Conjugates and Methods of Use
AR128331A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
AR128330A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
JP2025505650A (ja) 2022-02-07 2025-02-28 ビステラ， インコーポレイテッド 抗イディオタイプ抗体分子及びその使用
WO2023164516A1 (en) 2022-02-23 2023-08-31 Alector Llc Methods of use of anti-trem2 antibodies
US20250205350A1 (en) 2022-03-10 2025-06-26 Vivasor, Inc. Antibody-Drug Conjugates and Uses Thereof
US20250136672A1 (en) 2022-03-11 2025-05-01 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
JP2025509451A (ja) 2022-03-11 2025-04-11 ヤンセン ファーマシューティカ エヌ．ベー． 多重特異性抗体及びその使用
TW202400636A (zh) 2022-03-11 2024-01-01 比利時商健生藥品公司 多特異性抗體及其用途(一)
JP2025512785A (ja) 2022-03-23 2025-04-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体及び化学療法の併用処置
AU2023240941A1 (en) 2022-03-25 2024-09-19 Shanghai Henlius Biologics Co., Ltd. Anti-msln antibodies and methods of use
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
JP2025511000A (ja) 2022-03-28 2025-04-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト インターフェロンガンマバリアントおよびこれを含む抗原結合分子
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
JP2025510828A (ja) 2022-04-01 2025-04-15 ジェネンテック， インコーポレイテッド ポリペプチドを安定化するためのヒドロキシプロピルメチルセルロース誘導体
JP7701982B2 (ja) 2022-04-13 2025-07-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の薬学的組成物及び使用方法
AU2023253705A1 (en) 2022-04-13 2024-10-17 F. Hoffmann-La Roche Ag Pharmaceutical compositions of therapeutic proteins and methods of use
PE20251172A1 (es) 2022-04-26 2025-04-23 Novartis Ag Anticuerpos multiespecificos que se dirigen a il-13 e il-18
KR20250006932A (ko) 2022-05-03 2025-01-13 제넨테크, 인크. 항-Ly6E 항체, 면역접합체 및 이들의 용도
EP4522653A1 (en) 2022-05-11 2025-03-19 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
EP4527857A1 (en) 2022-05-17 2025-03-26 Suzhou Transcenta Therapeutics Co., Ltd. Bifunctional protein, and preparation thereof and use thereof
US20230416412A1 (en) 2022-05-31 2023-12-28 Hoffmann-La Roche Inc. Prevention or mitigation of t-cell engaging agent-related adverse effects
IL317449A (en) 2022-06-07 2025-02-01 Genentech Inc Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
WO2023239803A1 (en) 2022-06-08 2023-12-14 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
CN119585308A (zh) 2022-07-13 2025-03-07 基因泰克公司 针对用抗fcrh5/抗cd3双特异性抗体进行的治疗的给药
WO2024015993A1 (en) 2022-07-15 2024-01-18 Fibrogen, Inc. Modified anti-galectin-9 antibody and uses thereof
AU2023309556A1 (en) 2022-07-19 2025-01-23 F. Hoffmann-La Roche Ag Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
TW202417504A (zh) 2022-07-22 2024-05-01 美商建南德克公司 抗ｓｔｅａｐ１抗原結合分子及其用途
KR20250040994A (ko) 2022-07-22 2025-03-25 브리스톨-마이어스 스큅 컴퍼니 인간 pad4에 결합하는 항체 및 그의 용도
CN119866348A (zh) 2022-07-29 2025-04-22 艾莱克特有限责任公司 抗gpnmb抗体及其使用方法
IL317876A (en) 2022-07-29 2025-02-01 Alector Llc Transferrin receptor antigen binding domains and their uses
MA71622A (fr) 2022-07-29 2025-05-30 Alector Llc Domaines de liaison à l'antigène cd98hc et leurs utilisations
AU2023320453A1 (en) 2022-08-03 2025-02-06 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
WO2024040216A2 (en) 2022-08-19 2024-02-22 Fibrogen, Inc. Anti-ccr8 antibodies and uses thereof
CN120153254A (zh) 2022-09-01 2025-06-13 基因泰克公司 膀胱癌的治疗和诊断方法
AU2023342086A1 (en) 2022-09-15 2025-03-13 Voyager Therapeutics, Inc. Tau binding compounds
AU2023342647A1 (en) 2022-09-15 2025-02-20 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
KR20250131767A (ko) 2022-09-28 2025-09-03 발린크 테라퓨틱스 리미티드 다가 단백질 및 스크리닝 방법
EP4594345A1 (en) 2022-09-29 2025-08-06 F. Hoffmann-La Roche AG Protease-activated polypeptides
JP2025533355A (ja) 2022-10-05 2025-10-06 アルシーア セラピューティクス， インコーポレイテッド 気道炎症を処置するためのｎｏｔｃｈ４抗体、組成物および方法
TW202421664A (zh) 2022-10-07 2024-06-01 美商建南德克公司 用抗ｃ—ｃ模體趨化因子受體８（ｃｃｒ８）抗體治療癌症之方法
TW202430211A (zh) 2022-10-10 2024-08-01 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
TW202423970A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
TW202423969A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
WO2024079310A1 (en) 2022-10-14 2024-04-18 Ebbil, Ltd. Sil-6r and ctgf binding proteins and methods of use thereof
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
WO2024089551A1 (en) 2022-10-25 2024-05-02 Janssen Biotech, Inc. Msln and cd3 binding agents and methods of use thereof
IL320355A (en) 2022-10-25 2025-06-01 Genentech Inc Therapeutic and diagnostic methods for multiple myeloma
EP4612178A1 (en) 2022-11-03 2025-09-10 F. Hoffmann-La Roche AG Combination therapy with anti-cd19/anti-cd28 bispecific antibody
JP2025537197A (ja) 2022-11-08 2025-11-14 ジェネンテック， インコーポレイテッド 小児期発症特発性ネフローゼ症候群を治療するための組成物および方法
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
AR131163A1 (es) 2022-11-25 2025-02-19 Chugai Pharmaceutical Co Ltd Métodos para producir proteínas
JP2025538347A (ja) 2022-11-29 2025-11-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がん免疫療法の改善
CN119998314A (zh) 2022-12-08 2025-05-13 长春百克生物科技股份公司 特异性结合rsv的抗体
WO2024129594A1 (en) 2022-12-12 2024-06-20 Genentech, Inc. Optimizing polypeptide sialic acid content
CN120322461A (zh) 2022-12-23 2025-07-15 成都恩沐生物科技有限公司 新型抗gprc5d抗体
CN120693345A (zh) 2023-01-06 2025-09-23 艾利妥 抗il18结合蛋白抗体及其使用方法
WO2024149821A1 (en) 2023-01-13 2024-07-18 F. Hoffmann-La Roche Ag Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and venetoclax/azacitidine
EP4652198A1 (en) 2023-01-18 2025-11-26 Genentech, Inc. Multispecific antibodies and uses thereof
WO2024156672A1 (en) 2023-01-25 2024-08-02 F. Hoffmann-La Roche Ag Antibodies binding to csf1r and cd3
WO2024163494A1 (en) 2023-01-31 2024-08-08 F. Hoffmann-La Roche Ag Methods and compositions for treating non-small cell lung cancer and triple-negative breast cancer
WO2024163009A1 (en) 2023-01-31 2024-08-08 Genentech, Inc. Methods and compositions for treating urothelial bladder cancer
WO2024168061A2 (en) 2023-02-07 2024-08-15 Ayan Therapeutics Inc. Antibody molecules binding to sars-cov-2
WO2024186656A1 (en) 2023-03-03 2024-09-12 Arsenal Biosciences, Inc. Systems targeting psma and ca9
WO2024191785A1 (en) 2023-03-10 2024-09-19 Genentech, Inc. Fusions with proteases and uses thereof
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
CN120835901A (zh) 2023-03-13 2025-10-24 豪夫迈·罗氏有限公司 采用pd1-lag3双特异性抗体和hla-g t细胞双特异性抗体的组合疗法
EP4680748A1 (en) 2023-03-13 2026-01-21 Arsenal Biosciences, Inc. Synthetic pathway activators
EP4680638A1 (en) 2023-03-13 2026-01-21 F. Hoffmann-La Roche AG Treatment of cancer using an anti-hla-g/anti-cd3 bispecific antibody and a 4-1bb (cd137) agonist
AU2024248331A1 (en) 2023-03-31 2025-10-09 Genentech, Inc. Anti-alpha v beta 8 integrin antibodies and methods of use
WO2024211234A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211236A2 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211235A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024215948A1 (en) 2023-04-12 2024-10-17 Fusion Pharmaceuticals Inc. Steap2–targeted compounds and use thereof
CN121263210A (zh) 2023-04-17 2026-01-02 沛科生物公司 抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体
CN121038806A (zh) 2023-04-25 2025-11-28 阿森纳生物科学公司 用于转录调控的新颖受体
AU2024270495A1 (en) 2023-05-05 2025-10-09 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024231320A1 (en) 2023-05-08 2024-11-14 F. Hoffmann-La Roche Ag Targeted interferon alpha fusion proteins and methods of use
WO2024233646A1 (en) 2023-05-10 2024-11-14 Genentech, Inc. Methods and compositions for treating cancer
WO2024238537A1 (en) 2023-05-16 2024-11-21 F. Hoffmann-La Roche Ag Pd-1 -regulated il-2 immunocytokine and uses thereof
TW202449156A (zh) 2023-05-18 2024-12-16 美商克雷德治療股份有限公司 抑制天然殺手細胞對細胞療法之細胞毒性
TW202448933A (zh) 2023-05-31 2024-12-16 美商建南德克公司 用抗轉化生長因子β３抗體治療ＴＧＦβ相關病症之方法
CN121241068A (zh) 2023-06-01 2025-12-30 豪夫迈·罗氏有限公司 靶向bcma和cd28的双特异性抗体
WO2024246086A1 (en) 2023-06-01 2024-12-05 F. Hoffmann-La Roche Ag Immunostimulatory antigen binding molecules that specifically bind to bcma
AU2024305189A1 (en) 2023-06-16 2026-01-15 Valink Therapeutics Ltd Conjugated molecules
AU2024311339A1 (en) 2023-06-21 2026-01-08 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists
TW202504929A (zh) 2023-06-22 2025-02-01 美商建南德克公司 用於癌症治療之方法及組成物
TW202502809A (zh) 2023-06-22 2025-01-16 美商建南德克公司 抗體及其用途
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
WO2025021838A1 (en) 2023-07-26 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to cd3
US20250163182A1 (en) 2023-08-07 2025-05-22 Janssen Biotech, Inc. Enpp3 and cd3 binding agents and methods of use thereof
US20250136688A1 (en) 2023-08-07 2025-05-01 Janssen Biotech, Inc. Stabilized cd3 antigen binding agents and methods of use thereof
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
AU2024323186A1 (en) 2023-08-09 2026-01-15 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
TW202515614A (zh) 2023-08-25 2025-04-16 美商建南德克公司 治療非小細胞肺癌之方法及組成物
WO2025056655A1 (en) 2023-09-14 2025-03-20 F. Hoffmann-La Roche Ag Antibody formulation
AR133909A1 (es) 2023-09-25 2025-11-12 Hoffmann La Roche ANTICUERPO QUE SE UNE A C3bBb
WO2025072888A2 (en) 2023-09-28 2025-04-03 Novavax, Inc. Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
WO2025085489A1 (en) 2023-10-17 2025-04-24 Bristol-Myers Squibb Company Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
WO2025099120A1 (en) 2023-11-09 2025-05-15 F. Hoffmann-La Roche Ag Multispecific antibodies with conditional activity
WO2025106474A1 (en) 2023-11-14 2025-05-22 Genentech, Inc. Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
TW202523328A (zh) 2023-11-17 2025-06-16 美商建南德克公司 Ｍｃｌ－１抑制劑化合物及在抗體藥物結合物中之用途
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025126102A1 (en) 2023-12-12 2025-06-19 Janssen Biotech, Inc. Enpp3 × cd3 bispecific antibodies and use thereof
WO2025129010A1 (en) 2023-12-14 2025-06-19 Genentech, Inc. Methods of structure determination using antibodies
WO2025125386A1 (en) 2023-12-14 2025-06-19 F. Hoffmann-La Roche Ag Antibodies that bind to folr1 and methods of use
WO2025137523A2 (en) 2023-12-20 2025-06-26 Apogee Therapeutics, Inc. Pharmaceutical formulations of antibodies that bind interleukin 13
WO2025137086A1 (en) 2023-12-20 2025-06-26 Genentech, Inc. Reducing alpha-gal
WO2025132503A1 (en) 2023-12-20 2025-06-26 F. Hoffmann-La Roche Ag Antibodies binding to ceacam5
WO2025137410A1 (en) 2023-12-20 2025-06-26 Apogee Therapeutics, Inc. Pharmaceutical compositions of anti-il-13 antibodies with and without c-terminal lysine
WO2025133042A2 (en) 2023-12-22 2025-06-26 F. Hoffmann-La Roche Ag Activatable fusion proteins and methods of use
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins
WO2025166077A1 (en) 2024-01-31 2025-08-07 Alector Llc Compositions comprising progranulin and uses thereof
WO2025166045A1 (en) 2024-01-31 2025-08-07 Alector Llc β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
WO2025166042A1 (en) 2024-01-31 2025-08-07 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2025166040A1 (en) 2024-01-31 2025-08-07 Alector Llc Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
WO2025171006A1 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 binding protein compositions and methods of use
WO2025174974A1 (en) 2024-02-14 2025-08-21 Bristol-Myers Squibb Company Anti-cd33 antibodies and uses thereof
WO2025172924A1 (en) 2024-02-15 2025-08-21 Janssen Biotech, Inc. Anti-transferrin receptor compositions and methods thereof
WO2025181189A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191137A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of trop2-specific antigen binding proteins and cytokines
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025199346A1 (en) 2024-03-20 2025-09-25 Arsenal Biosciences, Inc. Antigen binding proteins that bind tmprss4 and methods of use thereof
US20250297255A1 (en) 2024-03-20 2025-09-25 Arsenal Biosciences, Inc. Systems targeting tmprss4 and slc34a2
WO2025215060A1 (en) 2024-04-11 2025-10-16 F. Hoffmann-La Roche Ag Antibodies that specifically bind modified oligonucleotides
WO2025226808A1 (en) 2024-04-24 2025-10-30 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2025233867A1 (en) 2024-05-10 2025-11-13 Adaptam Therapeutics, S.L. Anti-siglec-9 antibodies and uses thereof
WO2025238135A2 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Antibody with binding specificity for il-11
WO2025238133A1 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Multispecific antibody with binding specificity for il-11 and il-17
WO2025250969A1 (en) 2024-05-31 2025-12-04 Vertex Pharmaceuticals Incorporated Anti-cd74 antibodies, conjugates and uses thereof
WO2025255405A1 (en) 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Anti-fap antibodies and uses thereof
WO2025255353A1 (en) 2024-06-06 2025-12-11 Apogee Therapeutics, Inc. Dosage and administration of an anti-ox40l antibody
US20250376536A1 (en) 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Multispecific anti-cd40 / anti-fap antibodies and uses thereof
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
WO2025264572A1 (en) 2024-06-17 2025-12-26 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2025264972A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-4r alpha and antibodies that bind
WO2025264960A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-13 and antibodies that bind ox40l
US20260001942A1 (en) 2024-06-21 2026-01-01 H. Lundbeck A/S Treatment of headache disorders and/or psychiatric symptoms using anti-cgrp antibodies, and compositions and methods related thereto
WO2026003224A2 (en) 2024-06-26 2026-01-02 Iomx Therapeutics Ag Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132405A (en) * 1977-02-16 1979-01-02 Asher Nathan F Balanced swivel exercising device
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4479930A (en) * 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US5169774A (en) 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4938948A (en) * 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
JPS6360942A (ja) * 1986-08-01 1988-03-17 シタス　コ−ポレイシヨン インタ−ロイキン−２と共に免疫毒素又は抗体を用いてのコンビネ−ション治療
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
ATE243754T1 (de) * 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0469065B1 (en) * 1989-04-21 1996-05-29 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Recombinant antibody-toxin fusion protein
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU662311B2 (en) * 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0573551B1 (en) * 1991-02-27 2003-05-21 Micromet AG Serine-rich peptide linkers
EP0604580A1 (en) * 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) * 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
JPH07501451A (ja) * 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
AU676150B2 (en) * 1992-01-23 1997-03-06 Merck Patent Gmbh Monomeric and dimeric antibody-fragment fusion proteins
EP1997894B1 (en) * 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
WO1993021319A1 (en) * 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES

Also Published As

Publication number Publication date
AU3612293A (en) 1993-09-03
JP2005168489A (ja) 2005-06-30
JP2007228979A (ja) 2007-09-13
EP1997894A3 (en) 2009-11-04
EP1514934A2 (en) 2005-03-16
JPH08500962A (ja) 1996-02-06
JP2005104965A (ja) 2005-04-21
CA2129663A1 (en) 1993-08-19
JP2009035558A (ja) 2009-02-19
DE69334255D1 (de) 2009-02-12
DE69333807T2 (de) 2006-02-02
ATE419355T1 (de) 2009-01-15
EP0625200A1 (en) 1994-11-23
JP2007231027A (ja) 2007-09-13
WO1993016185A3 (en) 1993-09-30
US5877305A (en) 1999-03-02
US5837846A (en) 1998-11-17
ATE295420T1 (de) 2005-05-15
US5753204A (en) 1998-05-19
US20020168375A1 (en) 2002-11-14
US5534254A (en) 1996-07-09
DE69333807D1 (de) 2005-06-16
EP1997894A2 (en) 2008-12-03
JP2008289500A (ja) 2008-12-04
EP1997894B1 (en) 2011-03-30
JP4236493B2 (ja) 2009-03-11
EP0625200B1 (en) 2005-05-11
WO1993016185A2 (en) 1993-08-19
ATE503496T1 (de) 2011-04-15
CA2129663C (en) 2005-07-05
EP1514934A3 (en) 2006-04-19
AU675929B2 (en) 1997-02-27
JP2003284577A (ja) 2003-10-07
US20060147444A1 (en) 2006-07-06
US7138497B2 (en) 2006-11-21
CA2372813A1 (en) 1993-08-19
EP1514934B1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
ATE503496T1 (de) Biosynthetisches bindeprotein für tumormarker
BR9507594B8 (pt) Anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteína recombinante.
AU611202B2 (en) Recombinant antibody
EP1394253A4 (en) AGAINST HUMAN OVARIAN CARCINOMA AND CD3-ORIENTED BISPECIFIC ANTIBODY
CY1121451T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα κατα του ctla-4
GB2286399A (en) Recombinant humanized anti-cytomegalovirus antibodies
HUP9802401A2 (hu) Az emberi gp39-protein különböző epitópjaira specifikus monoklonális antitestek, valamint eljárások az ilyen antitestek diagnosztikai és terápiás alkalmazására
IL131406A0 (en) Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
ES2108732T3 (es) Anticuerpos humanizados anti-globulos de la grasa de la leche humana.
NO2006008I2 (no) Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
ATE508193T1 (de) Menschliches rezeptor für zytokine
DE69029808D1 (de) Monoklonale antikörper
Kipriyanov et al. Bacterial expression and refolding of single-chain Fv fragments with C-terminal cysteines
Adib-Conquy et al. Effect of amino acid substitutions in the heavy chain CDR3 of an autoantibody on its reactivity.
US20240167984A1 (en) Methods for detecting and determining protein structures and stability in fluids, including biological fluids
CN119039449B (zh) 抗人IgM抗体及其制备方法和用途
GB2598698A (en) Affinity-maturated anti-ASICIa antibodies
Carson et al. Monoclonal antibody recognizing rabbit IgG (Fab). A specific reagent for second antibody applications.
Vola et al. Recombinant proteins L and LG: two new tools for purification of murine antibody fragments
Nilson The bacterial cell wall molecules protein G and protein L: Characterization and use of their immunoglobulin binding properties.
Young et al. The circular dichroism of phosphocholine-specific mouse hybridoma and myeloma proteins: unusual properties of the hybridoma protein 101.6 G6
KR20230062232A (ko) Native C3에 특이적으로 결합하는 항체 및 이를 포함하는 경도인지장애 진단용 조성물
RU2021139258A (ru) Dll3-нацеливающие антитела и их применения
ATE281471T1 (de) Antikörper-testbesteck zur bestimmung von amylin
PEREMISLOV et al. Monoclonal antibodies against heavy and light chains of domestic mink IgG

Legal Events

Date Code Title Description
R071 Expiry of right

Ref document number: 1997894

Country of ref document: EP